Thera-SAbDab

1133 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)

Therapeutic	Format	Highest Clinical Trial (Feb '25)	Est. Status (Feb '25)	Target	Year Proposed	100% SI Struc.	99% SI Struc.	95-98% SI Struc.
abagovomab	Whole mAb	Phase-III	Discontinued	MUC16/CA125	2006	no	no	no
abazistobart	Whole mAb	TBC	TBC	PDCD1/CD279/PD1	2025	YES	no	no
abciximab	Fab	Approved	NFD	ITGA2B/CD41	1993	YES	no	no
abelacimab	Whole mAb	Phase-III	Active	F11	2018	YES	no	no
abiprubart	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2023	no	no	no
abituzumab	Whole mAb	Phase-II	Active	ITGAV/CD51	2013	no	no	no
abrezekimab	Fab	Phase-I	Discontinued	IL13	2017	no	no	no
abrilumab	Whole mAb	Phase-II	Discontinued	ITGA4B7	2014	no	no	no
acapatamab	Bispecific scFv	Phase-I/II	Discontinued	FOLH1/GCPII/PSMA;CD3E	2020	no;no	no;no	no;no
acasunlimab	Bispecific mAb	Phase-III	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2020	no;no	no;no	no;no
acimtamig	Bispecific (VH-VK-VH'-VL Homodimer)	Phase-II	Active	FCGR3A/CD16/CD16A;TNFRSF8/CD30	2023	no;no	no;no	YES;no
acrixolimab	Whole mAb	Phase-I/II	Active	PDCD1/CD279/PD1	2022	no	no	no
actoxumab	Whole mAb	Phase-III	Discontinued	Clostridium difficile Toxin A	2012	no	no	no
adakitug	Whole mAb	Phase-II	Active	CXCL8	2024	no	no	no
adalimumab	Whole mAb	Approved	Active	TNF/TNFA	1999	YES	YES	no
adebrelimab	Whole mAb	Approved	Active	PDL1/CD274	2019	no	no	no
adecatumumab	Whole mAb	Phase-II	Discontinued	EPCAM/CD326	2004	no	no	no
adezkibart	Whole mAb	TBC	TBC	FLT3LG	2025	no	no	no
adimanebart	Whole mAb	TBC	TBC	MUSK	2025	no	no	no
adintrevimab	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike	2021	no	YES	YES
aducanumab	Whole mAb	Approved	NFD	APP	2013	YES	no	no
afasevikumab	Whole mAb	Phase-I	Discontinued	IL17A	2015	YES	no	no
afimkibart	Whole mAb	Phase-III	Active	TNFSF15/TL1A/VEGI	2024	no	no	no
alacizumab	di-Fab	Phase-II	Discontinued	KDR/CD309/VEGFR2	2007	no	no	no
alcestobart	Whole mAb	Phase-II	Active	LAG3/CD223	2024	no	no	no
aldastotug	Whole mAb	Phase-I	Active	SIGLEC15/CD33L3	2024	no	no	no
alemtuzumab	Whole mAb	Approved	Active	CD52	2000	YES	no	no
aletekitug	Whole mAb	Phase-II	Active	IL18	2024	no	no	no
alextatug	Whole mAb	Phase-I	Discontinued	RNP complex containing PABPC1	2023	no	no	no
alirocumab	Whole mAb	Approved	Active	PCSK9	2012	no	no	no
alnuctamab	Bispecific mAb with Domain Crossover	Phase-I/II	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
alomfilimab	Whole mAb	Phase-II	Discontinued	ICOS/CD278	2020	YES	no	no
alpitatug	Whole mAb	TBC	Active	KLK2/KLK2A2/hGK-1/hK2	2024	no	no	no
alsevalimab	Whole mAb	Phase-I	Discontinued	VTCN1/B7H4	2019	no	no	no
amatuximab	Whole mAb	Phase-II	Discontinued	MSLN	2010	YES	YES	no
amdokitug	Whole mAb	TBC	TBC	IL17A	2025	no	no	no
amivantamab	Bispecific mAb	Approved	Active	EGFR/ERBB1/HER1;MET/HGFR	2019	no;YES	no;no	no;no
amlenetug	Whole mAb	Phase-III	Active	SNCA/PARK1/PARK4	2024	YES	no	no
amlitelimab	Whole mAb	Phase-III	Active	TNFSF4/CD134/CD252/OX40L	2020	no	no	no
amostomig	Bispecific mAb	Phase-I/Phase-II	Active	IAP/CD47/MER6/OA3;PDL1/CD274	2024	no;no	no;no	no;no
amrecibart	Whole mAb	TBC	TBC	F11	2025	no	no	no
amtabafusp	Whole mAb Fusion	TBC	Active	CD3E	2024	no	no	no
amubarvimab	Whole mAb	Phase-II/III	Discontinued	SARS-CoV-2 Spike RBD	2021	YES	YES	YES
amulirafusp	Whole mAb Fusion	Phase-I/II	Active	MS4A1/CD20	2024	no	YES	no
anbenitamab	Bispecific mAb	Phase-II/III	Active	ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV)	2020	no;YES	no;YES	YES;YES
andecaliximab	Whole mAb	Phase-III	Discontinued	MMP9/GELB	2016	YES	no	no
anetumab	Whole mAb ADC	Phase-II	Discontinued	MSLN	2013	YES	no	no
anifrolumab	Whole mAb	Approved	Active	IFNAR1	2013	YES	no	no
anivovetmab	Canine Whole mAb	Unknown	Active	Minor Capsid VP2 (Canine)	2022	no	no	YES
anrukinzumab	Whole mAb	Phase-II	Discontinued	IL13	2007	no	no	no
anselamimab	Whole mAb	Phase-III	Active	Light Chain Amyloid Fibrils	2021	no	no	no
ansipastobart	Whole mAb	Phase-I	Active	NT5E/CALJA/CD73	2024	no	no	no
ansuvimab	Whole mAb	Approved	Active	Zaire Ebolavirus Glycoprotein	2020	no	YES	no
anumigilimab	Whole mAb	Phase-I	Discontinued	CSF3R/CD114	2021	no	no	no
anvatabart	Whole mAb ADC	Phase-II/III	Active	ERBB2/CD340/HER2	2022	YES	YES	YES
anzurstobart	Whole mAb	Phase-I	Active	SIRPA	2022	YES	no	no
apamistamab	Whole mAb Radiolabelled	Phase-III	Active	PTPRC/CD45	2018	no	no	no
apitegromab	Whole mAb	Preregistration	Active	pro-MSTN/GDF8/GDF-8/pro-GDF8	2020	no	no	YES
aplitabart	Whole IgM+J Chain (Cyclic Pentamer)	Phase-I	Active	TNFRSF10B/CD262/DR5/TRAILR2	2024	no	no	no
aprutumab	Whole mAb ADC	Phase-I	Discontinued	FGFR2/CD332	2016	no	no	no
arcitumomab	Whole mAb	Approved (w)	NFD	CEA/CEACAM	1995	YES	no	no
armocibart	Whole mAb	TBC	Active	TFPI	2024	no	no	no
arumakimig	Bispecific mAb	TBC	TBC	IL18;IL1B	2025	no;no	no;YES	no;no
ascrinvacumab	Whole mAb	Phase-II	Discontinued	ACVRL1/SKR3	2015	no	no	no
aselizumab	Whole mAb	Phase-II	Discontinued	L-Selectin	2003	no	no	no
astegolimab	Whole mAb	Phase-III	Active	IL1RL1/ST2	2019	no	no	no
atenastobart	Whole mAb	Phase-I	Active	TNFRSF9/CD137/4-1BB	2024	no	no	no
atezolizumab	Whole mAb	Approved	Active	PDL1/CD274	2014	YES	YES	no
atibuclimab	Whole mAb	Phase-II	Active	CD14	2020	no	no	no
atidortoxumab	Whole mAb	Phase-II	Discontinued	Staphylococcus aureus Toxin A	2017	no	no	no
atigotatug	Whole mAb	Phase-III	Active	Fucosyl-GM1	2024	no	no	no
atinumab	Whole mAb	Phase-I	Discontinued	RTN4/Nogo	2010	no	no	no
atisnolerbart	Whole mAb	Phase-III	Active	Bet v 1	2022	YES	no	no
atoltivimab	Whole mAb	Phase-I	Discontinued	Zaire Ebolavirus Glycoprotein	2018	YES	no	no
avdoralimab	Whole mAb	Phase-II	Discontinued	C5AR1/CD88	2019	no	no	no
avelumab	Whole mAb	Approved	Active	PDL1/CD274	2015	YES	no	no
avitotamig	Whole mAb	TBC	Active	SIGLEC3/CD33/p67	2024	no	no	no
avizakimab	Whole mAb	Phase-I/II	Active	IL21	2019	no	no	no
axatilimab	Whole mAb	Preregistration	Active	CSF1R/CD115/M-CSFR	2019	no	no	no
azerutamig	Bispecific Mixed mAb and scFv-CH2-CH3	Phase-II	Active	KLRK1/NKG2D/CD314;ERBB2/CD340/HER2	2024	no;no	no;YES	no;YES
azintuxizumab	Whole mAb ADC	Phase-I	Discontinued	SLAMF7/CD319	2016	no	no	no
azirkitug	Whole mAb	Phase-I	Discontinued	CCR8/CKR-L1/CDw198	2024	no	no	no
bafisontamab	Bispecific Mixed mAb and Fab	Phase-I/II	Active	EGFR/ERBB1/HER1;MET/HGFR	2021	YES;no	no;no	no;no
balertatug	Whole mAb	TBC	TBC	CD70	2025	no	no	no
balonkibart	Whole mAb	TBC	TBC	NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA	2025	no	no	no
balstilimab	Whole mAb	Phase-III	Active	PDCD1/CD279/PD1	2018	no	no	no
bamlanivimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike	2020	YES	no	no
bapineuzumab	Whole mAb	Phase-II	Discontinued	APP	2005	no	no	YES
bapotulimab	Whole mAb	Phase-I	Active	ILDR2	2020	no	no	no
barecetamab	Whole mAb	Phase-I	Discontinued	ERBB3/HER3	2020	YES	no	no
barzolvolimab	Whole mAb	Phase-III	Active	KIT/CD117	2021	no	no	no
basiliximab	Whole mAb	Approved	NFD	IL2RA/CD25	1996	YES	no	no
batoclimab	Whole mAb	Preregistration	Active	FCGRT/FcRn	2019	no	no	no
bavituximab	Whole mAb	Phase-III	Active	Phosphatidylserine	2006	no	no	no
bavunalimab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	LAG3/CD223;CTLA4/CD152	2020	no;no	no;no	no;no
bebtelovimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2022	YES	no	no
becotatug	Whole mAb	Phase-III	Active	EGFR/ERBB1/HER1	2022	no	no	no
bedinvetmab	Canine Whole mAb	Approved	Active	NGFB (Canine)	2018	no	no	no
befovacimab	Whole mAb	Phase-II	Active	TFPI	2019	no	no	no
begelomab	Whole mAb	Phase-II/III	Active	DPP4/ADCP2/CD26	2014	no	no	no
belantamab	Whole mAb ADC	Approved	Active	TNFRSF17/CD269/BCMA/TNFRSF13A	2017	no	no	no
belimumab	Whole mAb	Approved	Active	TNFSF13B/CD257/BAFF	2003	YES	no	YES
belrestotug	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2022	no	no	no
beludavimab	Whole mAb	Phase-II	Discontinued	SARS-CoV-2 Spike RBD	2021	no	YES	no
bemarituzumab	Whole mAb	Phase-III	Active	FGFR2/CD332	2017	no	no	YES
bempikibart	Whole mAb	Phase-II	Active	IL7R/CD127	2022	no	no	no
benmelstobart	Whole mAb	Approved	Active	PDL1/CD274	2023	no	no	no
benralizumab	Whole mAb	Approved	Active	IL5RA/CD125	2009	no	no	no
bentracimab	Whole mAb	Phase-III	Active	AR-C124910XX	2020	YES	no	YES
benufutamab	Whole mAb	Phase-I/II	Active	TNFRSF10B/CD262/DR5/TRAILR2	2019	YES	no	no
bepranemab	Whole mAb	Phase-II	Active	MAPT	2019	no	no	no
berlimatoxumab	Whole mAb	Phase-II	Discontinued	Staphylococcus aureus Toxin A	2017	YES	no	no
bermekimab	Whole mAb	Preregistration (w)	Active	IL1A	2018	no	no	no
bersanlimab	Whole mAb	Phase-II	Discontinued	ICAM1/CD54	2017	no	no	no
besufetamig	Bispecific mAb	TBC	TBC	PDCD1/CD279/PD1;CD3E	2025	no;no	no;no	no;no
betifisolimab	Whole mAb	Phase-I/II	Active	PDL1/CD274	2022	no	no	no
betinukibart	Whole mAb	Phase-III	Active	IL17A	2024	YES	no	no
bevacizumab	Whole mAb	Approved	Active	VEGFA	2000	YES	no	YES
bexatamig	Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3	Phase-I/II	Active	IL3RA/CD123;NCR1/NKP46/NKp46/LY94/CD335	2024	YES;YES	no;no	no;no
bexmarilimab	Whole mAb	Phase-I/II	Active	STAB1	2019	no	no	no
bezetabart	Whole mAb ADC	Phase-I/II	Discontinued	CD74/HLA class II histocompatibility antigen gamma chain	2023	no	no	no
bezlotoxumab	Whole mAb	Approved	NFD	Clostridium difficile Toxin A	2012	YES	no	no
bifikafusp	Whole mAb Fusion	Preregistration	Active	FN extracellular domain B	2010	YES	no	no
bimagrumab	Whole mAb	Phase-II	Active	ACVR2B	2012	YES	YES	no
bimekizumab	Whole mAb	Approved	Active	IL17A	2013	YES	no	no
bintrafusp	Whole mAb Fusion	Approved	Active	PDL1/CD274	2015	YES	no	no
birinkibart	Whole mAb	TBC	Active	CSF2RB/CD131/IL3RB/IL5RB	2024	no	no	no
birtamimab	Whole mAb	Phase-III	Discontinued	SAA1	2018	no	no	no
bleselumab	Whole mAb	Phase-II	Discontinued	TNFRSF5/CD40	2015	YES	no	no
blinatumomab	Bispecific T-Cell Engager	Approved	Active	CD19;CD3E	2008	no;no	no;no	no;no
blontuvetmab	Canine Whole mAb	Unknown	Active	MS4A1/CD20	2015	no	no	YES
blosozumab	Whole mAb	Phase-II	Active	SOST	2011	no	no	no
bococizumab	Whole mAb	Phase-III	Discontinued	PCSK9	2013	YES	no	no
bocunebart	Whole mAb	TBC	TBC	ADCYAP1/PACAP	2025	no	no	no
bosakitug	Whole mAb	Phase-II	Active	TSLP	2024	no	no	no
boserolimab	Whole mAb	Phase-II	Active	TNFRSF7/CD27	2022	YES	no	no
botensilimab	Whole mAb	Phase-II/III	Active	CTLA4/CD152	2020	no	no	no
brazikumab	Whole mAb	Phase-III	Discontinued	IL23A	2016	no	no	no
bremzalerbart	Whole mAb	Phase-III	Active	Bet v 1	2022	YES	no	no
brenetafusp	Fusion Protein (scFv fused to TCR Fab)	Phase-III	Active	CD3	2023	no	no	no
brentuximab	Whole mAb ADC	Approved	Active	TNFRSF8/CD30	2010	no	no	no
briakinumab	Whole mAb	Preregistration (w)	Discontinued	IL12B/CLMFp40	2009	YES	no	no
briquilimab	Whole mAb	Phase-I/II	Discontinued	KIT/CD117	2022	no	no	no
brivekimig1	Trispecific Single Domains (VH-VH-VH'-VH''-VH'); Bispecific entry	Phase-II	Active	TNFSF4/CD134/CD252/OX40L;TNF/TNFA	2024	no;no	no;no	no;no
brivekimig2	Trispecific Single Domains (VH-VH-VH'-VH''-VH'); Monospecific entry	Phase-II	Active	ALB	2024	no	no	no
brivestobart	Whole mAb	Phase-I/II	Active	LAG3/CD223	2024	no	no	no
brodalumab	Whole mAb	Approved	Active	IL17RA/CD217	2011	no	no	no
brolucizumab	scFv	Approved	Active	VEGFA	2014	no	no	no
brontictuzumab	Whole mAb	Phase-I	Discontinued	NOTCH1	2014	no	no	no
budigalimab	Whole mAb	Phase-II/III	Active	PDCD1/CD279/PD1	2018	no	no	no
budoprutug	Whole mAb	Phase-I	Active	CD19	2023	no	no	no
bulumtatug	Whole mAb	TBC	Active	LAG3/CD223	2024	no	no	no
burfiralimab	Whole mAb	Phase-II	Active	VIM	2022	no	no	no
burosumab	Whole mAb	Approved	Active	FGF23	2016	YES	no	no
cabiralizumab	Whole mAb	Phase-II	Active	CSF1R/CD115/M-CSFR	2015	no	no	no
cabotamig	Bispecific (VH-G1CH1h-G4CH2CH3-scFv)	Phase-I	Active	CDH17;CD3E	2023	no;no	no;no	no;no
cadonilimab	Bispecific Mixed mAb and scFv	Approved	Active	PDCD1/CD279/PD1;CTLA4/CD152	2020	no;no	no;no	no;no
cafelkibart	Whole mAb	Phase-II	Active	CCR8/CKR-L1/CDw198	2024	no	no	no
calotatug	Whole mAb	Phase-I	Active	ERBB2/CD340/HER2	2024	no	no	no
calpurbatug	Whole mAb	Phase-I	Active	Bacteria Proteins HU and IHF	2022	no	no	no
camidanlumab	Whole mAb ADC	Phase-II	Active	IL2RA/CD25	2017	no	no	no
camoteskimab	Whole mAb	Phase-II	Active	IL18	2022	no	no	no
camrelizumab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2016	YES	no	no
canakinumab	Whole mAb	Approved	Active	IL1B	2007	no	YES	no
canrivitug	Whole mAb	TBC	Discontinued	SARS-CoV-2 RBD	2023	no	no	no
cantuzumab	Whole mAb ADC	Phase-II	Discontinued	MUC1/PEM/EMA	2003	no	no	no
caplacizumab	Nanobody	Approved	NFD	VWF	2011	YES	no	no
carlumab	Whole mAb	Phase-II	Discontinued	CCL2/MCP1	2010	no	YES	no
carotuximab	Whole mAb	Phase-II	Discontinued	ENG/CD105	2015	no	no	no
casdozokitug	Whole mAb	Phase-II	Active	IL27	2022	YES	no	no
caxmotabart	Whole mAb	Phase-III	Active	ERBB2/CD340/HER2	2024	YES	YES	YES
cemavafusp	Fusion Protein (Toxin fused to an scFv)	Phase-I	Active	PDL1/CD274	2023	no	no	no
cemiplimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2018	YES	no	no
cendakimab	Whole mAb	Phase-III	Active	IL13	2018	no	no	no
cenvacibart	Whole mAb	TBC	TBC	F11	2025	no	no	no
cenzestotug	Whole mAb	TBC	TBC	TNFRSF4/CD134/OX40	2025	no	no	no
cepeprubart	Whole mAb	Phase-II	Active	SELPLG/CD162/PSGL1	2023	no	no	no
cergutuzumab	Whole mAb Fusion	Phase-I	Discontinued	CEACAM5/CD66e	2015	no	no	no
certolizumab	Fab	Approved	Active	TNF/TNFA	2004	YES	no	no
cetrelimab	Whole mAb	Phase-III	Active	PDCD1/CD279/PD1	2017	no	no	no
cetuximab	Whole mAb	Approved	Active	EGFR/ERBB1/HER1	1999	YES	YES	YES
cevostamab	Bispecific mAb	Phase-I/II	Active	FCRL5/CD307;CD3	2019	no;no	no;no	no;no
cibisatamab	Bispecific mAb with Domain Crossover	Phase-I/II	Discontinued	CEACAM5/CD66e and CD3E;CD3E	2017	no;no	no;no	no;no
ciduvectamig	Bispecific mAb	Phase-I	Discontinued	TMEFF2;CD3E	2022	no;no	no;no	no;no
cifurtilimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2022	YES	no	no
ciletatug	Whole mAb	Phase-I/II	Active	CLDN18	2024	no	no	no
cilgavimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	YES
ciltistotug	Whole mAb	TBC	TBC	TNFRSF5/CD40	2025	no	no	no
cinpanemab	Whole mAb	Phase-II	Discontinued	SNCA/PARK1/PARK4	2018	YES	no	no
cinrebafusp	Fusion Protein	Phase-II	Active	ERBB2/CD340/HER2	2019	YES	YES	YES
cirevetmab	Canine Whole mAb	Unknown	Active	TGFB1 (Canine)	2022	no	no	no
citatuzumab	Fab Fusion	Phase-I	Discontinued	EPCAM/CD326	2008	no	no	no
cixutumumab	Whole mAb	Phase-II	Discontinued	IGF1R/CD221	2008	no	no	no
cizutamig	Bispecific Mixed Domains (L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa)	Phase-I	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2024	no;no	no;no	no;no
claseprubart	Whole mAb	TBC	TBC	C1S	2025	no	no	no
clazakizumab	Whole mAb	Phase-III	Active	IL6	2012	no	no	no
clervonafusp	di-Fab Fusion	Phase-II	Active	SLC29A2	2018	no	no	no
clesitamig	Bispecific Mixed Domains ((V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa)); Trispecific through dual targetting Fv2	Phase-I	Active	DLL3;CD3&TNFRSF9/CD137/4-1BB	2024	no;no	no;no	no;no
clesrovimab	Whole mAb	Preregistration	Active	RSV gpF	2022	YES	no	no
cliramitug	Whole mAb	TBC	TBC	Misfolded TTR	2025	no	no	no
clivatuzumab	Whole mAb Radiolabelled	Phase-III	Discontinued	MUC1/PEM/EMA	2009	no	no	no
cobolimab	Whole mAb	Phase-III	Active	HAVCR2/TIM3	2018	YES	no	no
codrituzumab	Whole mAb	Phase-II	Active	GPC3	2013	no	no	no
cofetuzumab	Whole mAb ADC	Phase-I	Discontinued	PTK7	2017	no	no	no
coltuximab	Whole mAb ADC	Phase-II	Active	CD19	2013	YES	no	no
comekibart	Whole mAb	Phase-III	Active	IL4R/CD124	2024	no	no	no
conatumumab	Whole mAb	Phase-II	Discontinued	TNFRSF10B/CD262/DR5/TRAILR2	2008	YES	no	no
concizumab	Whole mAb	Approved	Active	TFPI	2012	YES	no	no
coprelotamab	Whole mAb	Phase-III	Active	ERBB2/CD340/HER2	2020	YES	YES	YES
coramitug	Whole mAb	Phase-II	Active	Misfolded TTR	2023	no	no	no
cosfroviximab	Whole mAb	Phase-II	Active	Zaire Ebolavirus Glycoprotein	2016	no	YES	no
cosibelimab	Whole mAb	Approved	Active	PDL1/CD274	2019	no	no	no
crebankitug	Whole mAb	Phase-II	Active	IL7R/CD127	2024	no	no	no
crefmirlimab	scFv Engineered Dimer	Phase-III	Active	CD8A	2022	no	no	no
crenezumab	Whole mAb	Phase-II	Discontinued	APP	2011	YES	YES	no
crexavibart	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2022	no	YES	no
crizanlizumab	Whole mAb	Approved	Active	SELP/CD62	2016	no	no	no
crotedumab	Whole mAb	Phase-I	Discontinued	GCGR	2015	no	no	no
crovalimab	Whole mAb	Approved	Active	C5	2018	YES	no	no
crusekitug	Whole mAb	TBC	TBC	IL17A	2025	no	no	no
cudarolimab	Whole mAb	Phase-I	Discontinued	TNFRSF4/CD134/OX40	2019	no	no	no
cugrastomig	Bispecific Mixed mAb and scFv	Phase-I/II	Active	LAG3/CD223;PDCD1/CD279/PD1	2024	no;no	no;no	YES;no
cusatuzumab	Whole mAb	Phase-II	Active	CD70	2017	no	no	no
dacetuzumab	Whole mAb	Phase-II	Discontinued	TNFRSF5/CD40	2007	YES	no	no
daclizumab	Whole mAb	Approved	Active	IL2RA/CD25	1994	YES	no	no
dafsolimab	Whole mAb	Phase-III	Active	CD3E	2020	no	no	no
dalidnetug	Whole mAb	TBC	TBC	APP	2025	no	no	no
dalnicastobart	Whole mAb	Phase-I	Active	TNFRSF5/CD40	2022	no	no	no
dalotuzumab	Whole mAb	Phase-II	Discontinued	IGF1R/CD221	2009	no	no	no
dalutrafusp	Whole mAb Fusion	Phase-I	Discontinued	TGFBR2	2021	no	no	no
danburstotug	Whole mAb Fusion	Phase-III	Active	PDL1/CD274	2022	no	no	no
danvilostomig	Bispecific Mixed mAb and scFv	Phase-II	Discontinued	CTLA4/CD152;PDCD1/CD279/PD1	2022	YES;no	no;no	YES;no
dapirolizumab	Fab	Phase-III	Active	CD40LG/CD154	2013	no	no	no
daratumumab	Whole mAb	Approved	Active	ADPRC1/CD38	2009	YES	no	no
daretabart	Whole mAb	TBC	TBC	Ganglioside GD2	2025	no	no	no
dargistotug	Whole mAb	Phase-II	Active	TIGIT/WUCAM/VSTM3	2022	no	no	no
datopotamab	Whole mAb	Approved	Active	TACSTD2/TROP2/EGP1	2019	no	no	no
davutamig	Bispecific mAb	Phase-I/II	Active	MET/HGFR;MET/HGFR	2023	no;no	no;no	no;no
daxdilimab	Whole mAb	Phase-II	Active	LILRA4/CD85g	2020	no	no	no
dazukibart	Whole mAb	Phase-III	Active	IFNB1	2023	no	no	no
dectrekumab	Whole mAb	Phase-II	Discontinued	IL13	2014	no	no	no
delpacibart	Whole mAb	Phase-III	Active	TFRC/CD71	2022	no	no	no
demcizumab	Whole mAb	Phase-I	Discontinued	DLL4	2012	no	no	no
demupitamab	Whole mAb	Phase-I	Active	EGFR/ERBB1/HER1	2019	no	YES	no
denecimig	Bispecific mAb	Phase-III	Active	F9;F10	2022	no;YES	YES;no	no;no
denikitug	Whole mAb	Phase-I	Discontinued	CCR8/CKR-L1/CDw198	2024	no	no	no
denintuzumab	Whole mAb ADC	Phase-II	Discontinued	CD19	2014	no	no	no
denosumab	Whole mAb	Approved	Active	TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF	2005	no	no	no
denrakibart	Whole mAb	Phase-II	Active	CCL17/ABCD-2/SCYA17/TARC	2024	no	YES	no
depatuxizumab	Whole mAb ADC	Phase-III	Discontinued	EGFR/ERBB1/HER1	2016	no	no	no
depemokimab	Whole mAb	Phase-III	Active	IL5	2020	no	no	no
derlotuximab	Whole mAb Radiolabelled	Approved	Active	DNA/H1 Complex	2015	no	no	no
devextinetug	Whole mAb	Phase-II	Active	Metamphetamine	2022	no	no	no
dezamizumab	Whole mAb	Phase-II	Discontinued	APCS/SAP	2016	no	no	no
dibotatug	Whole mAb	Phase-I/II	Active	KLRD1/CD94	2024	no	no	no
dilpacimab	Bispecific mAb	Phase-II	Active	DLL4;VEGFA	2018	no;YES	no;no	no;YES
dinutuximab	Whole mAb	Approved	Active	Ganglioside GD2	2013	no	no	YES
diridavumab	Whole mAb	Phase-II	Active	Influenza A HA2	2014	YES	no	YES
disitamab	Whole mAb ADC	Approved	Active	ERBB2/CD340/HER2	2018	no	no	no
divozilimab	Whole mAb	Phase-III	Active	MS4A1/CD20	2020	no	no	no
docaravimab	Whole mAb (Mouse)	Approved	Active	Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-III	2019	no	no	no
domagrozumab	Whole mAb	Phase-II	Discontinued	MSTN/GDF8/GDF-8	2015	no	YES	no
domvanalimab	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2020	no	no	no
donanemab	Whole mAb	Approved	Active	APP	2018	no	no	no
donitabart	Whole mAb	Phase-I	Discontinued	Ganglioside GD2	2024	no	no	no
donzakimig1	Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry	Phase-I/II	Active	IL22;ALB	2023	no;no	no;YES	no;no
donzakimig2	Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Monospecific entry	Phase-I/II	Active	IL13	2023	no	no	no
dostarlimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2018	YES	no	no
dovanvetmab	Feline Whole mAb	Unknown	Active	IL31 (Feline)	2019	no	no	no
dresbuxelimab	Whole mAb	Phase-I/II	Active	NT5E/CALJA/CD73	2021	no	no	no
drotokibart	Whole mAb	Phase-III	Active	IL4R/CD124	2024	no	no	no
drozitumab	Whole mAb	Phase-II	Discontinued	TNFRSF10B/CD262/DR5/TRAILR2	2010	YES	no	no
duligotuzumab	Whole mAb	Phase-II	Discontinued	ERBB3/HER3	2012	no	no	YES
dupilumab	Whole mAb	Approved	Active	IL4R/CD124	2012	YES	no	no
durvalumab	Whole mAb	Approved	Active	PDL1/CD274	2014	YES	no	no
dusigitumab	Whole mAb	Phase-II	Discontinued	IGF1 and IGF2	2012	no	no	no
duvakitug	Whole mAb	Phase-II	Active	TNFSF15/TL1A/VEGI	2023	no	no	no
duvortuxizumab	Bispecific scFv with Crossover	Phase-I	Discontinued	CD19;CD3E	2016	no;no	no;no	no;no
ebdarokimab	Whole mAb	Approved	Active	IL12B/CLMFp40	2020	no	no	no
eblasakimab	Whole mAb	Phase-II	Active	IL13RA1/CD213A1	2021	no	no	YES
ebrasodebart	Whole mAb	Phase-I	Active	TMEM219/IGFBP-3R	2024	no	no	no
ebribafusp	Fusion Protein	Phase-II	Active	C3d	2024	YES	no	no
ebronucimab	Whole mAb	Approved	NFD	PCSK9	2020	no	no	no
eciskafusp	Fusion Protein	Phase-I	Active	PDCD1/CD279/PD1	2022	no	no	no
ecleralimab	Whole mAb	Phase-II	Active	TSLP	2021	no	no	no
eclutatug	Whole mAb	Phase-I/II	Active	CLDN1	2024	no	no	no
ecromeximab	Whole mAb	Phase-II	Discontinued	GD3 ganglioside	2002	no	no	no
eculizumab	Whole mAb	Approved	Active	C5	2002	YES	no	no
edrecolomab	Whole mAb	Approved (w)	NFD	EPCAM/CD326	1995	no	no	no
efalizumab	Whole mAb	Approved	NFD	ITGAL/CD11A/LFA1A	2001	YES	no	no
efungumab	scFv	Phase-III	Discontinued	Heat Shock Protein 90 Homolog	2006	no	no	no
eglatoprutug	Whole mAb	TBC	Active	KIT/CD117	2022	no	no	no
eldelumab	Whole mAb	Phase-II	Discontinued	CXCL10/IP10	2013	no	no	no
elegrobart	Whole mAb	TBC	TBC	TBC	2025	no	no	no
elezanumab	Whole mAb	Phase-II	Active	RGMA	2016	no	no	no
elgemtumab	Whole mAb	Phase-I/II	Discontinued	ERBB3/HER3	2014	no	no	YES
elipovimab	Whole mAb	Phase-I	Discontinued	HIV-1 gp120	2018	no	no	YES
elotuzumab	Whole mAb	Approved	NFD	SLAMF7/CD319	2008	no	no	no
elranatamab	Bispecific mAb	Approved	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2021	no;no	no;no	no;no
eltivutabart	Whole mAb	Phase-II	Active	ENTPD1/CD39	2024	no	no	no
eltrekibart	Whole mAb	Phase-II	Active	CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8	2023	YES	no	no
eluvixtamab	Bispecific scFv	Phase-I	Discontinued	SIGLEC3/CD33/p67;CD3E	2020	no;no	no;no	no;no
emactuzumab	Whole mAb	Phase-III	Active	CSF1R/CD115/M-CSFR	2014	YES	no	no
emapalumab	Whole mAb	Approved	NFD	IFNG	2016	no	no	no
emerfetamab	Bispecific scFv	Phase-I	Discontinued	SIGLEC3/CD33/p67;CD3E	2020	no;no	no;no	no;no
emfizatamab1	Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 1)	Phase-II	Active	CD3E;CD19	2022	no;no	no;no	no;no
emfizatamab2	Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 2)	Phase-II	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2022	no;no	no;no	no;no
emibetuzumab	Whole mAb	Phase-II	Active	MET/HGFR	2014	no	no	no
emicizumab	Bispecific mAb	Approved	NFD	F9;F10	2015	no;no	no;no	no;no
emiltatug	Whole mAb	Phase-I	Active	VTCN1/B7H4	2024	no	no	no
emirodatamab	Bispecific scFv-scFv-scFc	Phase-I	Discontinued	FLT3/CD135/FLK2;CD3E	2022	no;no	no;no	no;no
empasiprubart	Whole mAb	Phase-III	Active	C2	2022	YES	no	no
emugrobart	Whole mAb	Phase-II/III	Active	ENTPD1/CD39	2024	no	no	no
emunkitug	Whole mAb	Phase-I	Active	TNFRSF1B/TNFR2/CD120b/TNFR80/p75	2024	no	no	no
enapotamab	Whole mAb ADC	Phase-II	Discontinued	AXL/UFO	2017	no	no	no
enavatuzumab	Whole mAb	Phase-I	Discontinued	TNFRSF12A/CD266/TWEAKR	2010	no	no	no
encelimab	Whole mAb	Phase-I	Active	LAG3/CD223	2019	no	no	no
enfortumab	Whole mAb ADC	Approved	NFD	PVRL4/Nectin-4	2013	no	no	no
englumafusp	Fusion Protein	Phase-I	Active	CD19	2021	no	no	no
enibarcimab	Whole mAb	Phase-II	Active	ADM	2020	no	no	no
enlonstobart	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2023	no	no	YES
enoblituzumab	Whole mAb	Phase-II	Active	B7H3/CD276	2015	no	no	no
enokizumab	Whole mAb	Phase-II	Discontinued	IL9	2010	no	no	no
enoticumab	Whole mAb	Phase-I	Discontinued	DLL4	2012	no	no	no
enristomig	Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer)	Phase-I	Discontinued	PDL1/CD274;TNFRSF9/CD137/4-1BB	2023	no;no	no;no	no;no
ensituximab	Whole mAb	Phase-II	Active	MUC5AC	2010	no	no	no
enuzovimab	Whole mAb	Phase-I	Active	SARS-CoV-2 Spike RBD	2021	YES	no	no
envafolimab	Single Domain Variable Fragment;H	Approved	Active	PDL1/CD274	2018	no	no	no
enzelkitug	Whole mAb	TBC	TBC	CCR8/CKR-L1/CDw198	2025	no	no	no
epacmarstobart	Whole mAb	Phase-I	Discontinued	SIRPA	2022	no	no	no
epcoritamab	Bispecific mAb	Approved	Active	CD3E;MS4A1/CD20	2019	no;no	no;no	no;YES
epratuzumab	Whole mAb	Phase-III	Discontinued	SIGLEC2/CD22	1999	no	YES	no
eptinezumab	Whole mAb	Approved	Active	CALCA and CALCB	2016	no	no	no
eramkafusp	Whole mAb Fusion	Phase-I	Discontinued	MS4A1/CD20	2020	YES	YES	no
erenumab	Whole mAb	Approved	NFD	CALCRL	2016	YES	no	no
erfonrilimab	Bispecific Single Domains (VH-VH'-CH)	Phase-III	Active	PDL1/CD274;CTLA4/CD152	2020	no;YES	no;no	no;no
erlizumab	Whole mAb	Phase-II	Discontinued	ITGB2/CD18	2000	YES	no	no
ersodetug	Whole mAb	Phase-III	Active	INSR/CD220	2023	no	no	no
erzotabart	Whole mAb	Phase-I/II	Active	ADPRC1/CD38	2023	YES	no	no
etakafusp	Fusion Protein	Phase-I	Active	CD8	2024	no	no	no
etalanetug	Whole mAb	Phase-II/III	Active	MAPT	2024	no	no	no
etaracizumab	Whole mAb	Phase-II	Discontinued	ITGAVB3/CD61/VNR	2008	no	no	no
etentamig	Bispecific mAb	Phase-III	Active	CD3E;TNFRSF17/CD269/BCMA/TNFRSF13A	2024	no;no	no;no	no;no
etesevimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
etevritamab	Bispecific scFv	Phase-I	Discontinued	EGFR/ERBB1/HER1;CD3E	2020	no;no	no;no	no;no
etigilimab	Whole mAb	Phase-II	Active	TIGIT/WUCAM/VSTM3	2017	no	no	no
etokimab	Whole mAb	Phase-II	Discontinued	IL13	2018	no	no	no
etrolizumab	Whole mAb	Phase-III	Discontinued	ITGA4B7 and ITGAEB7	2010	no	no	no
etuptamig	Bispecific mAb	TBC	TBC	NCR3LG1/B7-H6;CD3E	2025	no;no	no;no	no;no
eurestobart	Whole mAb	Phase-I	Active	ENTPD1/CD39	2023	no	no	no
evalstotug	Whole mAb	Phase-I/II	Active	CTLA4/CD152	2023	no	no	no
evinacumab	Whole mAb	Approved	Active	ANGPTL3	2014	no	no	no
evolocumab	Whole mAb	Approved	Active	PCSK9	2012	no	no	no
evunzekibart	Whole mAb	Phase-I	Active	TNFRSF9/CD137/4-1BB	2022	YES	no	no
exbivirumab	Whole mAb	Phase-II	Discontinued	Hepatitis B Surface Antigen	2004	no	no	no
exerenibart	Whole mAb	TBC	TBC	TMPRSS6/MT2	2025	no	no	no
exidavnemab	Whole mAb	Phase-II	Active	SNCA/PARK1/PARK4	2021	no	no	no
exlinkibart	Whole mAb	Phase-II	Active	TNFRSF9/CD137/4-1BB	2022	no	no	no
ezabenlimab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2019	no	no	no
falbikitug	Whole mAb	Phase-II	Active	LIF	2023	YES	no	no
fanastomig	Bispecific (L-kappa-H-gamma1_G1(VH-CH1-h)_L-kappa)	Phase-I/II	Active	LAG3/CD223;PDCD1/CD279/PD1	2023	no;no	no;no	no;no
faricimab	Bispecific mAb	Approved	Active	VEGFA;ANGPT2	2017	YES;no	no;no	YES;YES
farletuzumab	Whole mAb	Phase-III	Discontinued	FOLR1	2008	no	no	no
fasinumab	Whole mAb	Phase-III	Discontinued	NGFB	2012	no	no	no
favezelimab	Whole mAb	Phase-II	Active	LAG3/CD223	2019	no	no	no
fazpilodemab	Bispecific mAb	Phase-II	Active	KLB;FGFR1/CD331/BFGFR	2022	no;no	no;no	no;no
feladilimab	Whole mAb	Phase-III	Active	ICOS/CD278	2019	no	no	no
felmetatug	Whole mAb	Phase-I	Active	VTCN1/B7H4	2024	no	no	no
felzartamab	Whole mAb	Preregistration	Active	ADPRC1/CD38	2019	no	no	no
fepixnebart	Whole mAb	Phase-II	Active	EREG	2022	YES	no	no
fezakinumab	Whole mAb	Phase-I	Discontinued	IL22	2009	no	no	no
fianlimab	Whole mAb	Phase-III	Active	LAG3/CD223	2019	no	no	no
ficerafusp	Fusion Protein	Phase-II/III	Active	EGFR/ERBB1/HER1	2024	YES	YES	YES
ficlatuzumab	Whole mAb	Phase-III	Active	HGF/SF	2011	no	no	no
fidasimtamab	Bispecific mAb	Phase-I	Discontinued	PDCD1/CD279/PD1;ERBB2/CD340/HER2	2021	no;YES	no;YES	no;YES
figitumumab	Whole mAb	Phase-I	Discontinued	IGF1R/CD221	2008	no	no	no
finotonlimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
firastotug	Whole mAb	Phase-I/II	Active	CTLA4/CD152	2023	no	no	no
firivumab	Whole mAb	Preclinical	Discontinued	Influenza A HA	2014	no	no	no
firsekibart	Whole mAb	TBC	TBC	IL1B	2025	no	no	no
fiztasovimab	Whole mAb	Phase-II	Active	Human Herpesvirus Glycoprotein B AD-1	2022	no	no	no
flanvotumab	Whole mAb	Phase-I	Discontinued	TYRP1	2011	no	no	no
fletikumab	Whole mAb	Phase-II	Discontinued	IL20	2013	no	no	no
flotetuzumab	Bispecific scFv with Crossover	Phase-I/II	Discontinued	IL3RA/CD123;CD3E	2017	no;no	no;no	no;no
fontolizumab	Whole mAb	Phase-II	Discontinued	IFNG	2002	no	YES	no
foralumab	Whole mAb	Phase-II	Active	CD3E	2010	no	no	no
foravirumab	Whole mAb	Phase-II	Discontinued	Rabies Virus Antigenic Site III	2008	no	no	no
forimtamig	Bispecific mAb with Domain Crossover	Phase-I/II	Discontinued	GPRC5D;CD3E	2022	no;no	no;no	no;no
fremanezumab	Whole mAb	Approved	Active	CALCA and CALCB	2016	no	no	no
freneslerbart	Whole mAb	Phase-III	Active	Fel d 1	2022	no	no	no
fresolimumab	Whole mAb	Phase-I	Discontinued	TGFB	2009	no	YES	no
frexalimab	Whole mAb	Phase-III	Active	CD40LG/CD154	2022	no	no	no
frovocimab	Whole mAb	Phase-II	Active	PCSK9	2018	no	no	no
frunevetmab	Feline Whole mAb	Unknown	Active	NGFB	2016	no	no	no
fulranumab	Whole mAb	Phase-III	Discontinued	NGFB	2010	no	YES	no
futermestotug	Whole mAb	TBC	TBC	CTLA4/CD152	2025	no	no	no
futuximab	Whole mAb	Phase-III	Active	EGFR/ERBB1/HER1	2012	no	no	no
gacovetug	Dimerised heavy domain (VH-h-CH2-CH3-CHS dimer)	TBC	Active	F4+ ETEC (Veterinary Application)	2024	YES	no	no
galcanezumab	Whole mAb	Approved	NFD	CALCA and CALCB	2015	no	no	no
galegenimab	Whole mAb	Phase-II	Discontinued	HTRA1	2021	YES	no	no
galiximab	Whole mAb	Phase-II	Discontinued	B7/CD80/CD28LG	2003	no	no	no
galvokimig1	Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry	TBC	Active	IL17A and IL17F;ALB	2023	YES;no	no;YES	no;no
galvokimig2	Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Monospecific entry	TBC	Active	IL13	2023	no	no	no
gancotamab	scFv	Phase-II	Discontinued	ERBB2/CD340/HER2	2018	no	no	no
ganitumab	Whole mAb	Phase-III	Discontinued	IGF1R/CD221	2010	no	no	no
gantenerumab	Whole mAb	Phase-III	Discontinued	APP	2012	YES	no	no
garadacimab	Whole mAb	Approved	NFD	F12	2018	YES	no	no
garetatug	Whole mAb ADC	TBC	TBC	CLDN18	2025	no	no	no
garetosmab	Whole mAb	Phase-III	Active	INHBA	2018	no	no	no
garivulimab	Whole mAb	Phase-I/II	Active	PDL1/CD274	2020	no	no	no
gatipotuzumab	Whole mAb	Phase-II	Active	MUC1/PEM/EMA	2016	no	no	no
gatralimab	Whole mAb	Phase-I	Discontinued	CD52	2019	YES	no	no
gedivumab	Whole mAb	Phase-II	Discontinued	Influenza A HA	2016	no	no	YES
gefurulimab	Bispecific Single Domains (VH-VH')	Phase-III	Active	C5;ALB	2022	no;YES	no;YES	no;no
gemtuzumab	Whole mAb ADC	Approved	NFD	SIGLEC3/CD33/p67	2016	YES	no	no
geptanolimab	Whole mAb	Preregistration	Active	PDCD1/CD279/PD1	2020	no	no	no
gevokizumab	Whole mAb	Phase-III	Active	IL1B	2010	YES	no	no
giloralimab	Whole mAb	Phase-I/II	Active	TNFRSF5/CD40	2019	no	no	no
gilvetmab	Canine Whole mAb	Unknown	Active	PDCD1/CD279/PD1 (Canine)	2016	no	no	no
gimistotug	Whole mAb	Phase-II	Active	TNFRSF4/CD134/OX40	2024	no	no	no
gimsilumab	Whole mAb	Phase-I	Discontinued	CSF2	2017	no	no	no
ginisortamab	Whole mAb	Phase-I/II	Active	GREM1	2021	YES	no	no
girentuximab	Whole mAb Radiolabelled	Phase-III	Discontinued	CA9	2009	no	no	no
givastomig	Bispecific (G1-scFv_L-kappa)	Phase-I	Active	CLDN18;TNFRSF9/CD137/4-1BB	2023	no;no	no;no	no;no
glembatumumab	Whole mAb ADC	Phase-III	Discontinued	GPNMB	2015	no	no	no
glenzocimab	Fab	Phase-II/III	Active	GP6	2018	YES	no	no
glofitamab	Bispecific mAb with Domain Crossover	Approved	Active	CD3E;MS4A1/CD20	2019	no;YES	no;YES	no;YES
gocatamig1	Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Bispecific entry	Phase-I/II	Active	CD3E;ALB	2024	no;no	no;no	no;YES
gocatamig2	Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Monospecific entry	Phase-I/II	Active	DLL3	2024	no	no	no
golimumab	Whole mAb	Approved	Active	TNF/TNFA	2004	YES	no	no
golocdacimab	Whole mAb	Phase-II	Discontinued	OLR1/LOX1	2022	YES	no	no
gontivimab	Bispecific Single Domains (VH-VH'-VH')	Phase-II	Discontinued	Respiratory Syncytial Virus Glycoprotein F;Respiratory Syncytial Virus Glycoprotein F	2019	no;no	no;no	no;no
gorivitug	Whole mAb	Phase-I	Active	SARS-CoV-2 Spike RBD	2022	no	no	no
gosuranemab	Whole mAb	Phase-II	Discontinued	MAPT	2018	no	no	no
gotistobart	Whole mAb	Phase-III	Active	CTLA4/CD152	2023	YES	no	no
gremubamab	Bispecific mAb	Phase-II	Discontinued	PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas)	2019	no;no	no;no	YES;no
gresonitamab	Bispecific scFv-scFv-scFc	Phase-I	Discontinued	CLDN18;CD3E	2021	no;no	no;no	no;no
greziprubart	Whole mAb	Phase-I/II	Active	C5	2024	no	no	no
grisnilimab	Whole mAb	Phase-I/II	Active	CD7	2020	no	no	no
gruticibart	Whole mAb	Phase-II	Active	F11	2023	no	no	no
gulgafafusp	Fusion Protein (whole mAb with protein)	Phase-III	Active	GLP1R	2023	no	no	no
gumokimab	Whole mAb	Phase-III	Active	IL17A	2021	no	no	no
guselkumab	Whole mAb	Approved	Active	IL23A	2013	YES	no	no
ianalumab	Whole mAb	Phase-III	Active	TNFRSF13C/CD268/BAFFR/BR3	2017	no	no	no
ibalizumab	Whole mAb	Approved	NFD	CD4	2007	YES	no	no
ibentatug	Whole mAb	Phase-I/II	Active	CSP1	2023	no	no	no
ibramvibart	Whole mAb	TBC	TBC	SARS-CoV-2 Spike RBD	2025	no	no	no
ibritumomab	Whole mAb	Approved	NFD	MS4A1/CD20	1999	YES	no	no
icrucumab	Whole mAb	Phase-II	Discontinued	FLT1	2010	no	no	no
idactamab	Whole mAb	Phase-I	Discontinued	SLC1A5	2020	no	no	no
idarucizumab	Fab	Approved	NFD	Dabigatran	2013	YES	no	no
ieramilimab	Whole mAb	Phase-II	Active	LAG3/CD223	2018	no	no	no
ifabotuzumab	Whole mAb	Phase-II	Active	EPHA3	2015	no	no	no
ifinatamab	Whole mAb	Phase-III	Active	B7H3/CD276	2022	no	no	no
iladatuzumab	Whole mAb ADC	Phase-I	Discontinued	AGM6/CD79B	2017	no	no	no
iluzanebart	Whole mAb	Phase-II	Active	TREM2	2023	no	no	no
imalumab	Whole mAb	Phase-II	Discontinued	MIF	2014	YES	YES	no
imaprelimab	Whole mAb	Phase-I	Discontinued	MCAM/CD146/MUC18	2017	no	no	no
imeroprubart	Whole mAb	TBC	Active	FCGRT/FcRn	2024	no	no	no
imgatuzumab	Whole mAb	Phase-II	Discontinued	EGFR/ERBB1/HER1	2012	no	no	no
imneskibart	Whole mAb	Phase-I/II	Active	IL2RA/CD25	2024	no	no	no
imsidolimab	Whole mAb	Phase-III	Active	IL36R	2020	no	no	no
imvotamab	Pentameric IgM with Fused scFv (Bispecific)	Phase-II	Active	CD3E;MS4A1/CD20	2022	no;no	no;no	no;no
imzokitug	Whole mAb	Phase-II	Active	CCR8/CKR-L1/CDw198	2024	no	no	no
inclacumab	Whole mAb	Phase-II	Discontinued	SELP/CD62	2011	no	no	no
indatuximab	Whole mAb ADC	Phase-II	Discontinued	SDC1/CD138	2011	no	no	no
indematug	Whole mAb	TBC	Active	IFNG	2024	no	no	no
indenebart	Whole mAb	Phase-II	Active	SNCA/PARK1/PARK4	2024	no	no	no
indusatumab	Whole mAb ADC	Phase-II	Discontinued	GUCY2C	2014	no	no	no
inebilizumab	Whole mAb	Approved	Active	CD19	2015	no	no	no
inezetamab	Bispecific Mixed mAb and scFv	Phase-I	Active	CD40;MSLN	2022	no;no	no;no	no;no
infliximab	Whole mAb	Approved	NFD	TNF/TNFA	1997	YES	no	no
ingitamig	Bispecific Mixed mAb and tandem mAb/scFv	Phase-I	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;KLRK1/NKG2D/CD314	2024	no;no	no;no	no;no
inlecitug	Whole mAb	TBC	TBC	KDR/CD309/VEGFR2	2025	no	no	no
inotuzumab	Whole mAb ADC	Approved	Active	SIGLEC2/CD22	2004	no	no	no
intetumumab	Whole mAb	Phase-II	Discontinued	ITGAVB3/CD61/VNR	2009	no	no	no
invikafusp	Fusion Protein	Phase-II	Active	TRBV6&TRBV10	2024	YES	no	no
iparomlimab	Whole mAb	Preregistration	Active	PDCD1/CD279/PD1	2021	no	no	no
ipilimumab	Whole mAb	Approved	Active	CTLA4/CD152	2005	YES	no	YES
iratumumab	Whole mAb	Phase-II	Discontinued	TNFRSF8/CD30	2005	no	no	no
isatuximab	Whole mAb	Approved	Active	ADPRC1/CD38	2014	YES	no	no
iscalimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2017	no	no	no
isecarosmab	Bispecific Single Domains (VH-VH')	Phase-I	Discontinued	ADAMTSL5;ALB	2019	no;no	no;no	no;YES
ispectamab	Whole mAb	Phase-I	Active	TNFRSF17/CD269/BCMA/TNFRSF13A	2022	no	no	no
istiratumab	Bispecific Mixed mAb and scFv	Phase-II	Discontinued	IGF1R/CD221;ERBB3/HER3	2017	no;no	no;no	no;no
isuventatug	Whole mAb	TBC	TBC	MICA&MICB	2025	no	no	no
itanistomig	Bispecific Mixed Domains (VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa)	TBC	Active	PDL1/CD274;IAP/CD47	2024	YES;no	no;no	no;no
itepekimab	Whole mAb	Phase-III	Active	IL33	2019	no	no	no
itolizumab	Whole mAb	Approved	Active	CD6	2010	no	no	no
ivicentamab	Bispecific mAb	Phase-I/II	Active	CD37;CD37	2021	no;no	no;no	no;no
ivonescimab	Bispecific (G1-kappa_scFv)	Approved	Active	VEGFA;PDCD1/CD279/PD1	2021	YES;no	no;no	YES;no
ivuxolimab	Whole mAb	Phase-II	Active	TNFRSF4/CD134/OX40	2019	no	no	no
ixekizumab	Whole mAb	Approved	Active	IL17A	2011	YES	YES	no
ixotatug	Whole mAb ADC	TBC	TBC	CLDN6	2025	no	no	no
izalontamab	Bispecific Mixed mAb and scFv	Phase-III	Active	EGFR/ERBB1/HER1;ERBB3/HER3	2022	YES;no	YES;no	YES;no
izastobart	Whole mAb	Phase-I	Active	C5AR1/CD88	2023	no	no	no
izeltabart	Whole mAb	Phase-I/II	Discontinued	ADAM9	2022	no	no	no
izenivetmab	Canine Whole mAb	Unknown	Active	NGFB (Canine)	2022	no	no	no
izuralimab	Bispecific Mixed mAb and scFv	Phase-II	Discontinued	ICOS/CD278;PDCD1/CD279/PD1	2020	no;no	no;no	no;no
labetuzumab	Whole mAb ADC	Phase-II	Discontinued	CEACAM5/CD66e	2015	no	no	no
lacnotuzumab	Whole mAb	Phase-II	Discontinued	CSF1	2016	no	no	no
lacutamab	Whole mAb	Phase-II	Active	KIR3DL2/CD158K	2018	no	no	no
ladiratuzumab	Whole mAb ADC	Phase-II	Active	SLC39A6/ZIP6	2017	no	no	no
lampalizumab	Fab	Phase-III	Discontinued	CFD	2012	YES	no	no
lanadelumab	Whole mAb	Approved	NFD	KLKB1	2015	YES	no	no
lancastotug	Whole mAb	Phase-I	Active	TIGIT/WUCAM/VSTM3	2023	no	no	no
landogrozumab	Whole mAb	Phase-II	Discontinued	MSTN/GDF8/GDF-8	2015	no	no	no
lanerkitug	Whole mAb	Phase-I	Active	CCR8/CKR-L1/CDw198	2024	no	no	no
laprituximab	Whole mAb ADC	Phase-I	Discontinued	EGFR/ERBB1/HER1	2015	no	no	no
larcaviximab	Whole mAb	Phase-II	Active	Zaire Ebolavirus Glycoprotein	2016	no	YES	no
lasrekibart	Whole mAb	TBC	TBC	IL5	2025	no	no	no
latikafusp	Whole mAb Fusion	Phase-I	Discontinued	PDCD1/CD279/PD1	2022	no	no	no
latozinemab	Whole mAb	Phase-III	Active	SORT1/Gp95/NT3	2020	no	no	no
laventatug	Whole mAb ADC	TBC	TBC	SLC39A6/ZIP6	2025	no	no	no
lebrikizumab	Whole mAb	Approved	Active	IL13	2009	YES	no	no
lecanemab	Whole mAb	Approved	Active	APP	2019	no	no	no
lecankitug	Whole mAb	TBC	TBC	IL17A&IL17F	2025	no	no	no
ledostomig	Bispecific Mixed mAb and scFv	TBC	TBC	NT5E/CALJA/CD73;PDCD1/CD279/PD1	2025	no;no	no;no	no;no
lemalesomab	Whole mAb	Phase-I	Discontinued	NCA90/p95	2002	no	no	no
lemzoparlimab	Whole mAb	Phase-III	Active	IAP/CD47	2020	no	no	no
lenvervimab	Whole mAb	Phase-III	Active	Hepatitis B Virus	2017	no	no	no
lenzilumab	Lenzilumab	Preregistration	Active	CSF2	2014	no	no	no
lepunafusp	Whole mAb Fusion	Phase-I/II	Active	TfR1/CD71	2021	no	no	no
lerdelimumab	Whole mAb	Phase-III	Discontinued	TGFB1	2002	no	no	no
leronlimab	Whole mAb	Approved	Active	CCR5/CD195	2017	no	no	no
lesabelimab	Whole mAb	Phase-II	Active	PDL1/CD274	2022	no	no	no
lesofavumab	Whole mAb	Phase-I	Discontinued	Influenza B Virus	2016	no	no	no
letaplimab	Whole mAb	Phase-I/II	Active	IAP/CD47	2020	no	no	no
letolizumab	Single Domain Variable Fragment;H	Phase-I/II	Active	CD40LG/CD154	2016	no	no	no
levilimab	Whole mAb	Approved	Active	IL6R/CD126	2018	no	no	no
lexatumumab	Whole mAb	Phase-I	Discontinued	TNFRSF10B/CD262/DR5/TRAILR2	2006	no	no	YES
libevitug	Whole mAb	Phase-II	Active	Hepatitis B Virus Surface Antigen	2024	no	no	YES
libivirumab	Whole mAb	Phase-II	Discontinued	Hepatitis B Virus Surface Antigen	2004	no	no	no
licaminlimab	scFv	Phase-II	Active	TNF/TNFA	2020	no	no	no
lifastuzumab	Whole mAb ADC	Phase-II	Discontinued	SLC34A2	2013	no	no	no
ligelizumab	Whole mAb	Phase-III	Active	IGHE	2012	YES	no	no
ligufalimab	Whole mAb	Phase-III	Active	IAP/CD47	2021	no	no	no
lilotomab	Whole mAb ADC	Phase-II	Active	CD37	2014	no	no	no
linavonkibart	Whole mAb	Phase-I	Active	TGFB1	2022	no	no	no
linclatamig	Bispecific mAb	Phase-I	Discontinued	LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23;CD3E	2024	no;no	no;no	no;no
lintuzumab	Whole mAb Radiolabelled	Phase-II	Discontinued	SIGLEC3/CD33/p67	1996	no	no	no
linvoseltamab	Bispecific mAb	Preregistration	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2022	no;no	no;no	no;no
lipustobart	Whole mAb	Phase-I	Discontinued	PDCD1/CD279/PD1	2022	no	no	no
lirentelimab	Whole mAb	Phase-III	Discontinued	SIGLEC8/SAF2	2020	no	YES	no
lirilumab	Whole mAb	Phase-II	Discontinued	KIRD2	2012	YES	no	no
litifilimab	Whole mAb	Phase-III	Active	CLEC4C	2022	no	no	no
livmoniplimab	Whole mAb	Phase-II/III	Active	LRRC32	2021	no	no	no
lixudebart	Whole mAb	Phase-II	Active	CLDN1	2023	no	no	no
lodapolimab	Whole mAb	Phase-I	Discontinued	PDL1/CD274	2019	no	no	no
lodelcizumab	Whole mAb	Phase-II	Discontinued	PCSK9	2012	no	no	no
lofacimig	Bispecific Tandem VH Domains fused to G1 Constant Domain	TBC	Active	F11;F11	2024	no;no	no;no	no;no
lokivetmab	Canine Whole mAb	Approved	NFD	IL31	2014	no	no	no
lomtegovimab	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2021	no	no	no
lomvastomig	Bispecific mAb with Domain Crossover	Phase-II	Active	PDCD1/CD279/PD1;HAVCR2/TIM3	2022	no;no	no;no	no;no
loncastuximab	Whole mAb ADC	Approved	Active	CD19	2017	no	YES	no
lonigutamab	Whole mAb	Phase-I/II	Active	IGF1R/CD221	2020	no	no	no
lorigerlimab	Bispecific Mixed scFv (scFv-CH2-CH3-scFv)	Phase-II	Active	PDCD1/CD279/PD1;CTLA4/CD152	2021	no;no	no;no	no;YES
lorukafusp	Whole mAb Fusion	Phase-II	Active	Ganglioside GD2	2018	no	no	YES
lorvotuzumab	Whole mAb ADC	Phase-II	Discontinued	NCAM1/CD56	2010	no	no	no
losatuxizumab	Whole mAb ADC	Phase-I	Discontinued	EGFR/ERBB1/HER1	2016	no	no	no
lotivibart	Whole mAb	TBC	Active	HIV-1 gp120	2024	no	no	YES
lucatumumab	Whole mAb	Phase-I	Discontinued	TNFRSF5/CD40	2007	no	no	no
lucorafusp	Whole mAb	Phase-I	Active	TIGIT/WUCAM/VSTM3	2024	no	no	no
lulizumab	Single Domain Variable Fragment;L	Phase-II	Active	CD28	2014	no	no	no
lumiliximab	Whole mAb	Phase-II	Discontinued	FCER2/CD23	2004	no	YES	no
lumistobart	Whole mAb	Phase-I	Active	SIRPA	2024	no	no	no
lumretuzumab	Whole mAb	Phase-I/II	Discontinued	ERBB3/HER3	2014	YES	no	no
lumrotatug	Whole mAb	Phase-II	Active	ADPRC1/CD38	2023	no	no	no
lunaxafusp	Fusion Protein	TBC	Active	ERBB2/CD340/HER2	2022	no	no	no
lunlekitug	Whole mAb	TBC	Active	IL1A	2024	no	no	no
lunsekimig1	Trispecific and Pentavalent (sc-5-VH); Bispecific entry	Phase-II	Active	IL13;IL13	2023	no;no	no;no	no;no
lunsekimig2	Trispecific and Pentavalent (sc-5-VH); Bispecific entry	Phase-II	Active	TSLP;ALB	2023	no;no	no;no	no;YES
lunsekimig3	Trispecific and Pentavalent (sc-5-VH); Monospecific entry	Phase-II	Active	TSLP	2023	no	no	no
lupartumab	Whole mAb ADC	Phase-I	Discontinued	LYPD3	2016	no	no	no
lusvertikimab	Whole mAb	Phase-III	Active	IL7R/CD127	2020	no	no	no
lutikizumab	Bispecific Dual Variable Domain IG	Phase-II	Discontinued	IL1A;IL1B	2016	no;no	no;no	no;no
luvagrobart	Whole mAb	Phase-I	Active	NGF	2023	no	no	YES
luveltamab	Whole mAb ADC	Phase-II/III	Active	FOLR1	2022	no	no	no
maftivimab	Whole mAb	Preregistration	Discontinued	Zaire Ebolavirus Glycoprotein	2018	YES	no	no
magrolimab	Whole mAb	Phase-III	Active	IAP/CD47	2018	no	YES	no
manelimab	Whole mAb	Phase-I	Discontinued	PDL1/CD274	2019	no	no	no
manfidokimab	Whole mAb	Phase-III	Active	IL4R/CD124	2021	no	no	no
margetuximab	Whole mAb	Approved	Active	ERBB2/CD340/HER2	2013	no	no	no
maridebart	Whole mAb	Phase-II	Active	GIPR	2023	YES	no	no
marlotamig	Bispecific mAb	Phase-II	Active	EGFR/ERBB1/HER1;CD28	2024	no;no	no;no	no;no
marstacimab	Whole mAb	Approved	Active	ERBB2/CD340/HER2	2013	no	no	no
masavibart	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
matuzumab	Whole mAb	Phase-II	Discontinued	EGFR/ERBB1/HER1	2003	YES	YES	no
mavrilimumab	Whole mAb	Phase-II	Active	CSF2RA/CD116	2009	no	no	no
mavrostobart	Whole mAb	Phase-I	Active	NT5E/CALJA/CD73	2024	no	no	no
mazorelvimab	Whole mAb	Phase-III	Active	Rabies Virus Spike Glycoprotein G	2021	no	no	no
mecbotamab	Whole mAb	Phase-II	Active	AXL/UFO	2022	no	no	no
melredableukin	Whole mAb Fusion	Phase-II	Active	Non-Binding	2021	no	YES	YES
melrilimab	Whole mAb	Phase-II	Discontinued	IL1RL1/ST2	2020	no	no	no
mepolizumab	Whole mAb	Approved	Active	IL5	1999	no	no	no
metelimumab	Whole mAb	Phase-II	Discontinued	TGFB1	2003	YES	YES	no
mevonlerbart	Whole mAb	Phase-III	Active	Fel d 1	2022	YES	no	no
mezagitamab	Whole mAb	Phase-II	Active	ADPRC1/CD38	2019	no	no	no
mibavademab	Whole mAb	Phase-III	Active	LEPR/CD295/OBR	2020	no	no	no
micvotabart	Whole mAb	Phase-I/II	Active	FN extracellular domain B	2024	no	YES	no
milatuzumab	Whole mAb	Phase-I/II	Discontinued	CD74/HLA class II histocompatibility antigen gamma chain	2007	no	no	no
mipasetamab	Whole mAb	Phase-I	Discontinued	AXL/UFO	2020	no	no	no
mipletamig	Bispecific Mixed scFv (scFv-CH2-CH3-scFv)	Phase-I	Active	IL3RA/CD123;CD3E	2024	no;no	no;no	no;no
miptenalimab	Whole mAb	Phase-II	Active	LAG3/CD223	2019	no	no	no
mirikizumab	Whole mAb	Approved	Active	IL23A	2017	no	no	no
miromavimab	Whole mAb (Mouse)	Approved	NFD	Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-II	2019	no	no	no
mirvetuximab	Whole mAb ADC	Approved	Active	FOLR1	2015	no	no	no
mirzotamab	Whole mAb	Phase-I	Discontinued	B7H3/CD276	2019	no	no	no
misitatug	Whole mAb	Phase-II	Active	MSLN	2024	no	no	no
mitazalimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2017	no	no	no
modakafusp	Whole mAb Fusion	Phase-II	Discontinued	ADPRC1/CD38	2019	no	no	no
modotuximab	Whole mAb	Phase-III	Active	EGFR/ERBB1/HER1	2012	no	no	no
moflerafusp	Fusion Protein	TBC	TBC	SIRPA	2025	no	no	no
mogamulizumab	Whole mAb	Approved	Active	CCR4/CD194	2010	no	no	no
monalizumab	Whole mAb	Phase-III	Active	KLRC1	2015	no	no	no
mosunetuzumab	Bispecific mAb	Approved	Active	CD3E;MS4A1/CD20	2017	no;no	no;no	no;YES
motavizumab	Whole mAb	Phase-III	Discontinued	Respiratory Syncytial Virus Glycoprotein F	2006	YES	YES	no
moxetumomab	Fv Fusion	Approved	NFD	SIGLEC2/CD22	2009	no	no	no
mozistobart	Whole mAb	Phase-I/II	Active	SIGLEC2/CD22	2024	no	no	no
mupadolimab	Whole mAb	Phase-II	Active	NT5E/CALJA/CD73	2021	no	no	no
murlentamab	Whole mAb	Phase-II	Active	AMHR2	2018	no	no	no
muromonab	Whole mAb	Approved (withdrawn)	Discontinued	CD3E	1988	YES	no	no
muzastotug	Whole mAb	Phase-I/II	Active	CTLA4/CD152	2023	no	no	no
nadecnemab	Whole mAb	Phase-II	Active	GFRA3	2020	no	no	no
nadunolimab	Whole mAb	Phase-III	Active	IL1RAP	2018	no	no	no
namilumab	Whole mAb	Phase-II	Active	CSF2	2010	no	no	no
naptumomab	Fab Fusion	Phase-III	Discontinued	TPBG/WAIF1	2006	no	no	no
naratuximab	Whole mAb ADC	Phase-II	Active	CD37	2015	no	no	no
narlumosbart	Whole mAb	Phase-III	Approved	TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF	2022	no	no	no
narnatumab	Whole mAb	Phase-I	Discontinued	MST1R/CD136	2011	no	no	no
narsoplimab	Whole mAb	Preregistration	Active	MASP2	2019	no	no	no
natalizumab	Whole mAb	Approved	Active	ITGA4/CD49D	1998	no	YES	no
navenibart	Whole mAb	Phase-II	Active	KLKB1	2024	YES	no	no
navicixizumab	Bispecific mAb	Phase-II	Active	DLL4;VEGFA	2015	no;no	no;no	no;no
navivumab	Whole mAb	Preclinical	Discontinued	Influenza A HA	2015	YES	YES	no
naxitamab	Whole mAb	Approved	Active	Ganglioside GD2	2018	no	no	no
nebokitug	Whole mAb	Phase-II	Active	CCL24/SCYA24/Ckb-6/MPIF-2/eotaxin-2	2024	no	no	no
nebratamig1	Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1)	Phase-I/II	Active	TNFRSF9/CD137/4-1BB;PDL1/CD274	2023	no;no	no;no	no;no
nebratamig2	Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2)	Phase-I/II	Active	ROR1;CD3D and CD3E	2023	no;no	no;no	no;no
necitumumab	Whole mAb	Approved	Active	EGFR/ERBB1/HER1	2008	YES	no	no
negalstobart	Whole mAb	Phase-II	Active	LAG3/CD223	2023	no	no	no
nelistotug	Whole mAb	Phase-II	Active	TACTILE/CD96	2023	no	no	no
nelmastobart	Whole mAb	Phase-I/II	Active	BTN1A1	2023	no	no	no
nemolizumab	Whole mAb	Approved	Active	IL31RA	2014	no	no	no
nepuvibart	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	no	no	no
nesfrotamig	Bispecific Mixed mAb and scFv	TBC	TBC	ERBB2/CD340/HER2;TNFRSF9/CD137/4-1BB	2025	YES;no	YES;no	YES;no
nesvacumab	Whole mAb	Phase-I	Discontinued	ANGPT2	2012	no	no	no
netakimab	Whole mAb	Approved	Active	IL17A	2017	no	no	no
nezastomig	Bispecific mAb	Phase-I/II	Active	FOLH1/GCPII/PSMA;CD28	2023	no;no	no;no	no;no
nezutatug	Whole mAb	Phase-I/II	Active	ERBB3/HER3	2023	no	no	no
nimacimab	Whole mAb	Phase-II	Active	CNR1/CB1	2018	no	no	no
nimotuzumab	Whole mAb	Approved	Active	EGFR/ERBB1/HER1	2005	no	YES	no
nipocalimab	Whole mAb	Preregistration	Active	FCGRT/FcRn	2019	no	no	YES
nirsevimab	Whole mAb	Approved	Active	Respiratory Syncytial Virus	2018	YES	no	YES
nisevokitug	Whole mAb	Phase-III	Active	TGFB1/TGFB2	2022	no	no	no
nivatrotamab	Bispecific Mixed mAb and scFv	Phase-I/II	Active	GD2;CD3E	2020	no;no	no;no	no;no
nivisnebart	Whole mAb	TBC	Active	SORT1/Gp95/NT3	2024	no	no	no
nivolumab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2012	YES	no	no
nofazinlimab	Whole mAb	Phase-III	Active	PDCD1/CD279/PD1	2021	no	no	no
nolavetbart	Whole mAb (Canine)	Unknown	Active	IL31RA (Canine)	2023	no	no	no
nurulimab	Whole mAb	Phase-I	Discontinued	CTLA4/CD152	2019	no	YES	no
nuvustotug	Whole mAb	Phase-I	Active	TNFRSF4/CD134/OX40	2024	no	no	no
oberotatug	Whole mAb	Phase-I	Active	LY75/CD205/DEC205	2023	no	no	no
obertamig	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	CD3E;HLA-G	2023	no;no	no;no	no;no
obexelimab	Whole mAb	Phase-III	Active	CD19	2018	no	no	no
obiltoxaximab	Whole mAb	Approved	NFD	Anthrax Protective Antigen	2015	no	no	no
obinutuzumab	Whole mAb	Approved	Active	MS4A1/CD20	2008	YES	YES	YES
obrindatamab	Bispecific scFv with Domain Crossover	Phase-I	Discontinued	B7H3/CD276;CD3E	2020	no;no	no;no	no;no
obrixtamig	Bispecific mAb (L-kappa-H-gamma1_L-lambda-H-gamma1)	Phase-II	Active	DLL3;CD3E	2024	no;no	no;no	no;no
ocankitug	Whole mAb	Phase-II	Active	TSLP	2024	no	no	no
ocaratuzumab	Whole mAb	Phase-II	Discontinued	MS4A1/CD20	2012	no	no	no
ociperlimab	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2020	YES	no	no
ocrelizumab	Whole mAb	Approved	NFD	MS4A1/CD20	2005	no	no	YES
odesivimab	Whole mAb	Approved	Active	Zaire Ebolavirus Glycoprotein	2019	YES	no	no
odronextamab	Bispecific mAb	Approved	Active	MS4A1/CD20;CD3E	2019	no;no	no;no	no;no
ofatumumab	Whole mAb	Approved	Active	MS4A1/CD20	2005	YES	no	no
ogalvibart	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2022	YES	no	no
olaratumab	Whole mAb	Approved	Active	PDGFRA/CD140A	2010	no	no	no
oleclumab	Whole mAb	Phase-III	Active	NT5E/CALJA/CD73	2016	no	no	no
olendalizumab	Whole mAb	Phase-II	Discontinued	C5	2015	no	no	no
olintatug	Whole mAb	TBC	Active	KAAG1/RU2AS	2024	no	no	no
olinvacimab	Whole mAb	Phase-II	Active	KDR/CD309/VEGFR2	2018	no	no	no
oloctinebart	Whole mAb	TBC	Active	LGALS3/GAL3	2023	no	no	no
olokizumab	Whole mAb	Approved	Active	IL6	2010	YES	no	no
omalizumab	Whole mAb	Approved	Active	IGHE	2000	YES	YES	YES
omburtamab	Whole mAb Radiolabelled	Preregistration	Active	B7H3/CD276	2018	YES	no	no
omectatug	Whole mAb	Phase-III	Active	CLDN18	2024	no	no	no
omodenbamab	Whole mAb	Phase-I/II	Active	Staphylococcus aureus Protein A	2020	no	no	no
omoprubart	Whole mAb	Phase-I/II	Active	C5	2023	no	no	no
ompekimig1	Trispecific Mixed mAb and scFv; Bispecific entry	TBC	TBC	IL13;IL4	2025	no;no	no;no	no;no
ompekimig2	Trispecific Mixed mAb and scFv; Monospecific entry	TBC	TBC	IL33	2025	no	no	no
onartuzumab	Fab + di-Fc	Phase-III	Discontinued	MET/HGFR	2010	YES	no	no
onfekafusp	Whole mAb Fusion	Phase-III	Active	FN extracellular domain B	2010	YES	no	no
ongericimab	Whole mAb	Approved	Active	PCSK9	2019	no	no	no
ontamalimab	Whole mAb	Phase-III	Discontinued	MADCAM1	2018	YES	no	no
ontuxizumab	Whole mAb	Phase-II	Active	CD248/CD164L1	2013	no	no	no
onvatilimab	Whole mAb	Phase-I	Discontinued	VSIR/VISTA/B7H5/PD1H/SISP1	2017	no	no	no
opamistomig	Bispecific Mixed mAb and scFv	TBC	TBC	PDL1/CD274;TNFRSF9/CD137/4-1BB	2025	no;no	no;no	no;no
opelkibart	Whole mAb ADC	Phase-I	Discontinued	KIT/CD117	2023	no	no	no
opicinumab	Whole mAb	Phase-II	Discontinued	LINGO1	2015	YES	no	no
oportuzumab	scFv	Preregistration	Discontinued	EPCAM/CD326	2008	no	no	no
opucolimab	Whole mAb	Phase-I	Discontinued	PDL1/CD274	2019	no	no	no
opugotamig	Bispecific Mixed mAb and scFv ((G1_L-kappa)_scFvkh-G1(h-CH2-CH3))	Phase-I	Active	FOLR1;FOLR1	2024	no;no	no;no	no;no
ordesekimab	Whole mAb	Phase-II	Active	IL15	2020	no	no	no
orilanolimab	Whole mAb	Phase-II	Discontinued	FCGRT/FcRn	2018	YES	no	no
ormutivimab	Whole mAb	Approved	NFD	Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1	2021	no	YES	no
orticumab	Whole mAb	Phase-II	Active	OxLDL	2012	no	no	no
osemitamab	Whole mAb	Phase-II	Active	CLDN18	2022	no	no	no
osocimab	Whole mAb	Phase-II	Discontinued	F11	2018	no	YES	no
otelixizumab	Whole mAb	Phase-II	Active	CD3E	2007	no	no	no
otilimab	Whole mAb	Phase-III	Discontinued	CSF2	2018	no	YES	YES
otlertuzumab	di-scFv+Fc	Phase-II	Discontinued	CD37	2013	no	no	no
oturkibart	Whole mAb	TBC	TBC	IL4R/CD124	2025	no	no	no
oxelumab	Whole mAb	Phase-II	Discontinued	TNFSF4/CD134/CD252/OX40L	2010	no	no	no
ozanezumab	Whole mAb	Phase-II	Discontinued	RTN4/Nogo	2012	no	no	no
ozekibart	VH-IgG	Phase-I	Discontinued	TNFRSF10B/CD262/DR5/TRAILR2	2023	no	no	no
ozoralizumab	Bispecific Single Domains (VH-VH'-VH)	Approved	NFD	TNF/TNFA;ALB	2011	YES;YES	no;no	YES;no
ozureprubart	Whole mAb	Phase-II	Active	IGHE	2024	no	no	no
ozuriftamab	Whole mAb	Phase-II	Active	ROR2	2022	no	no	no
pabinafusp	Whole mAb Fusion	Approved	Active	TFRC/CD71	2018	no	no	no
pacanalotamab	Bispecific scFv	Phase-I	Discontinued	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
pacibekitug	Whole mAb	Phase-II	Active	IL6	2024	no	no	no
pacmilimab	Whole mAb	Phase-II	Active	PDL1/CD274	2019	no	no	no
palivizumab	Whole mAb	Approved	NFD	Respiratory Syncytial Virus Glycoprotein F	1998	no	YES	no
palverafusp	Fusion Protein	Phase-I/II	Active	VEGF	2024	YES	YES	no
pamlectabart	Whole mAb	Phase-I/II	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2024	YES	no	YES
pamrevlumab	Whole mAb	Phase-III	Active	CTGF/CCN2	2015	no	no	no
pamvatamig	Bispecific mAb	Phase-I/II	Discontinued	MET/HGFR;EGFR/ERBB1/HER1	2023	no;no	no;no	no;no
panitumumab	Whole mAb	Approved	Active	EGFR/ERBB1/HER1	2004	YES	no	no
panobacumab	Whole mAb	Phase-II	Active	Serotype IATS O11	2008	no	no	no
paridiprubart	Whole mAb	Phase-III	Active	TLR4/CD284	2022	YES	no	YES
parsatuzumab	Whole mAb	Phase-II	Discontinued	EGFL7	2012	no	no	no
pasotuxizumab	Bispecific scFv	Phase-I	Discontinued	FOLH1/GCPII/PSMA;CD3E	2014	no;no	no;no	no;no
pasritamig	Bispecific Mixed Domains ((H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3))	Phase-I	Active	KLK2/KLK2A2/hGK-1/hK2;CD3E	2024	no;no	no;no	no;no
patecibart	Whole mAb	Phase-I	Discontinued	EDNRA	2023	no	no	no
pateclizumab	Whole mAb	Phase-II	Discontinued	LTA	2011	YES	no	no
patritumab	Whole mAb	Phase-III	Discontinued	ERBB3/HER3	2011	no	no	no
pavurutamab	Bispecific scFv	Phase-I	Discontinued	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
pegrizeprument	Fab (VH-G1CH1h_L-kappa)	TBC	Active	CD28	2024	no	no	no
pelgifatamab	Whole mAb ADC	Phase-I	Discontinued	FOLH1/GCPII/PSMA	2020	no	no	no
peluntamig	Bispecific Whole mAb	Phase-I/II	Active	IAP/CD47;DLL3	2024	no;no	no;no	no;no
pembrolizumab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2013	YES	no	no
pemivibart	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2023	no	no	YES
penpulimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
pepinemab	Whole mAb	Phase-II	Active	SEMA4D/CD100	2018	no	no	no
perakizumab	Whole mAb	Phase-I	Discontinued	IL17A	2012	no	no	no
perenostobart	Whole mAb	Phase-II	Discontinued	ENTPD1/CD39	2022	no	no	no
peresolimab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2022	no	no	no
pertuzumab	Whole mAb	Approved	Active	ERBB2/CD340/HER2	2003	YES	YES	YES
petosemtamab	Bispecific mAb	Phase-I	Discontinued	EGFR/ERBB1/HER1;LGR5	2019	no;no	no;no	no;no
pexelizumab	scFv	Phase-III	Discontinued	C5	2002	no	YES	no
picankibart	Whole mAb	Preregistration	Active	IL23A	2023	no	no	no
pidilizumab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2012	no	no	no
pimivalimab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2020	no	no	no
pimurutamab	Whole mAb	Phase-II	Active	EGFR/ERBB1/HER1	2019	no	no	no
pinatuzumab	Whole mAb ADC	Phase-II	Discontinued	SIGLEC2/CD22	2012	no	YES	no
pivekimab	Whole mAb	Phase-I/II	Active	IL3RA/CD123	2021	no	no	no
placulumab	Single Domain Variable Fragment (VL) + Fc	Phase-II	Discontinued	TNF/TNFA	2012	no	no	no
plamotamab	Bispecific Mixed mAb and scFv	Phase-II	Active	MS4A1/CD20;CD3E	2018	no;no	no;no	no;no
plonmarlimab	Whole mAb	Phase-II/III	Active	CSF2	2020	no	no	no
plozalizumab	Whole mAb	Phase-II	Active	CCR2/CD192	2015	no	no	no
plutavimab	Whole mAb	Phase-II	Active	SARS-CoV-2 Spike RBD	2022	no	no	no
podentamig1	Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl); Bispecific entry	Phase-I	Active	TNFRSF17/BCM/BCMA/CD269/TNFRSF13A;ALB	2024	no;no	no;no	no;YES
podentamig2	Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl); Monospecific entry	Phase-I	Active	CD3E	2024	no	no	no
polatuzumab	Whole mAb ADC	Approved	Active	AGM6/CD79B	2012	no	no	no
polzastobart	Whole mAb	Phase-I/II	Active	LILRB2	2022	no	no	no
ponezumab	Whole mAb	Phase-II	Discontinued	APP	2010	YES	no	no
ponsegromab	Whole mAb	Phase-I	Discontinued	GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB	2020	no	no	no
porgaviximab	Whole mAb	Phase-II	Discontinued	Zaire Ebolavirus Glycoprotein	2016	no	YES	no
porustobart	VH-CH2-CH3	Phase-II	Active	CTLA4/CD152	2022	YES	no	no
posdinemab	Whole mAb	Phase-II	Active	MAPT	2022	no	no	no
posnafusp	Fab Fusion Protein	TBC	Active	TFRC/CD71	2024	no	no	no
potravitug	Whole mAb	Phase-II/III	Active	BK polyomavirus VP1	2025	no	no	no
pozelimab	Whole mAb	Approved	Active	C5	2018	no	no	no
pradusinstobart	Whole mAb	Phase-I	Discontinued	PDCD1/CD279/PD1	2022	no	no	no
prafnosbart	Whole mAb	Phase-I	Discontinued	ACVR1	2022	no	no	no
praluzatamab	Whole mAb	Phase-II	Active	ALCAM/CD166	2019	no	no	no
prasinezumab	Whole mAb	Phase-II	Active	SNCA/PARK1/PARK4	2017	no	no	no
precemtabart	Whole mAb	Phase-I	Active	CEACAM5/CD66e	2024	no	no	no
prezalumab	Whole mAb	Phase-II	Discontinued	ICOSLG	2015	YES	no	no
pritoxaximab	Whole mAb	Phase-II	Discontinued	Shiga Toxin Type 1	2012	no	no	no
pritumumab	Whole mAb	Phase-II	Active	VIM	2003	no	no	no
produvofusp	Nanobody Fusion Protein	TBC	Active	TBC	2024	no	no	no
prolgolimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2018	no	no	no
pucotenlimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
pulocimab	Whole mAb	Phase-III	Active	KDR/CD309/VEGFR2	2021	no	YES	no
pumitamig1	Bispec Mixed Domains (Fv entry)	TBC	TBC	VEGFA	2025	YES	no	YES
pumitamig2	Bispec Mixed Domains (Single domain entry;H)	TBC	TBC	PDL1/CD274	2025	YES	no	no
puxitatug	Whole mAb	Phase-I/II	Active	VTCN1/B7H4	2023	no	no	no
quavonlimab	Whole mAb	Phase-II	Active	CTLA4/CD152	2019	no	no	no
quetmolimab	Whole mAb	Phase-II	Discontinued	CX3CL1	2018	no	no	no
quilizumab	Whole mAb	Phase-II	Discontinued	IGHE	2011	YES	no	no
quisovalimab	Whole mAb	Phase-II	Active	TNFSF14/CD258	2021	no	no	no
racotumomab	Whole mAb	Approved	Active	Idiotope of anti-NeuGc-ganliosides	2008	no	no	no
rademikibart	Whole mAb	Phase-III	Active	IL4R/CD124	2023	no	no	no
radretumab	di-scFv + CH4	Phase-II	Discontinued	FN extracellular domain B	2010	YES	no	no
rafivirumab	Whole mAb	Phase-II	Discontinued	Rabies Virus Antigenic Site III	2008	YES	no	no
ragifilimab	Whole mAb	Phase-II	Active	TNFRSF18/CD357/GITR	2019	no	no	no
ragistomig	Bispecific (G1-scFv_L-kappa)	Phase-I	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2023	no;no	no;no	no;no
ralpancizumab	Whole mAb	Phase-I	Discontinued	PCSK9	2013	no	no	YES
raludotatug	Whole mAb	Phase-II/III	Active	CDH6	2022	no	no	no
ralzapastotug	Whole mAb	Phase-I	Discontinued	TIGIT/WUCAM/VSTM3	2022	no	no	no
ramantamig1	Trispecific Mixed mAb and scFv; Bispecific entry	TBC	TBC	CD3E;GPRC5D	2025	no;no	no;no	no;no
ramantamig2	Trispecific Mixed mAb and scFv; Monospecific entry	TBC	TBC	TNFRSF17/CD269/BCMA/TNFRSF13A	2025	no	no	no
ramucirumab	Whole mAb	Approved	Active	KDR/CD309/VEGFR2	2008	YES	no	no
ranevetmab	Canine Whole mAb	Unknown	Active	NGFB	2016	no	no	no
ranibizumab	Fab	Approved	Active	VEGFA	2004	YES	no	YES
rapaprutug	Whole mAb	TBC	TBC	KARS1	2025	no	no	no
ravagalimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2017	YES	no	YES
ravulizumab	Whole mAb	Approved	Active	C5	2017	no	YES	no
recaticimab	Whole mAb	Approved	Active	PCSK9	2020	no	no	no
recibokibart	Whole mAb	Phase-II/III	Active	IL1RL2/IL1Rrp2/IL1RRP2/IL-36R/IL36R	2024	no	no	no
refanezumab	Whole mAb	Phase-II	Discontinued	SIGLEC4/MAG	2015	no	no	no
reflocibart	Whole mAb	Phase-II	Discontinued	VEGFB	2023	no	no	no
regdanvimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
relatlimab	Whole mAb	Approved	Active	LAG3/CD223	2018	no	YES	no
relfovetmab	Feline Whole mAb	Unknown	Active	NGFB	2018	no	no	no
remternetug	Whole mAb	Phase-III	Active	APP	2023	no	no	no
remtolumab	Bispecific Dual Variable Domain IG	Phase-II	Discontinued	IL17A;TNF/TNFA	2016	YES;no	YES;no	no;no
remzistotug	Whole mAb	TBC	Active	PVRIG/NECTIN2 receptor/CD112R	2024	no	no	no
renvistobart	Whole mAb	Phase-II	Active	TIGIT/WUCAM/VSTM3	2023	YES	no	no
reozalimab	Bispecific mAb	Phase-I/II	Discontinued	PDCD1/CD279/PD1;PDL1/CD274	2022	no;no	no;no	no;no
reslizumab	Whole mAb	Approved	Active	IL5	2001	no	no	no
resugosbart	Whole mAb	Phase-II	Active	SOST	2022	no	no	no
retavibart	Whole mAb	TBC	TBC	RSV gpF	2025	no	no	no
retifanlimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2019	no	no	no
retlirafusp	Whole mAb Fusion	Phase-III	Active	PDL1/CD274	2020	no	no	no
revdofilimab	Whole mAb	Phase-I	Discontinued	TNFRSF4/CD134/OX40	2019	no	no	no
rezetamig	Bispecific (half G4-kappa_G4(VH-h-CH2-CH3))	Phase-I	Discontinued	CD3;SIGLEC2/CD22	2023	no;no	no;no	no;no
rezorstobart	Whole mAb	Phase-I/II	Active	KLRB1	2023	no	no	no
riliprubart	Whole mAb	Phase-III	Active	C1S	2023	no	no	no
rilogrotug	Whole mAb	Phase-I	Active	GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB	2024	no	no	no
rilotumumab	Whole mAb	Phase-II	Discontinued	HGF/SF	2009	no	no	no
riltovetbart	Whole mAb	Unknown	Active	IL31 (Canine)	2022	no	no	no
rilvegostomig	Bispecific mAb	Phase-III	Active	PDCD1/CD279/PD1;TIGIT/WUCAM/VSTM3	2022	no;no	no;no	no;no
rimteravimab	Mixed Nanobody (VHH-CH2-CH3 dimer)	Phase-I/II	Active	SARS-CoV-2 Spike RBD	2021	no	no	no
rinatabart	Whole mAb	Phase-III	Active	FOLR1	2024	no	no	no
rinucumab	Whole mAb	Phase-II	Discontinued	PDGFRB/CD140B	2015	no	no	no
ripertamab	Whole mAb	Approved	Active	MS4A1/CD20	2019	YES	YES	no
risankizumab	Whole mAb	Approved	Active	IL23A	2015	no	no	no
rituximab	Whole mAb	Approved	Active	MS4A1/CD20	1997	YES	YES	YES
rivabazumab	Fab	Phase-II	Discontinued	PcrV type III secretion system	2015	no	no	no
robatumumab	Whole mAb	Phase-II	Discontinued	IGF1R/CD221	2008	no	no	no
rocatinlimab	Whole mAb	Phase-III	Active	TNFRSF4/CD134/OX40	2021	no	no	no
roconkibart	Whole mAb	Phase-III	Active	IL17A	2023	no	no	no
roledumab	Whole mAb	Phase-II/III	Active	RhD/CD240D/RhPI	2010	no	no	no
rolinsatamab	Whole mAb ADC	Phase-I	Discontinued	PRLR	2018	no	no	no
rolistobart	Whole mAb	TBC	Active	LILRB4/CD85K	2023	no	no	no
romilkimab	Bispecific Dual Variable Domain IG	Phase-II	Discontinued	IL13;IL4	2017	no;no	no;no	no;no
romlusevimab	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2021	no	YES	no
romosozumab	Whole mAb	Approved	NFD	SOST	2011	no	no	no
rontalizumab	Whole mAb	Phase-II	Discontinued	IFNA1	2009	YES	no	no
rosmantuzumab	Whole mAb	Phase-I	Discontinued	RSPO3	2016	no	no	no
rosnilimab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2022	no	no	no
rosopatamab	Whole mAb	Phase-III	Active	FOLH1/GCPII/PSMA	2019	no	no	no
rovalpituzumab	Whole mAb ADC	Phase-III	Discontinued	DLL3	2015	no	no	no
rovelizumab	Whole mAb	Phase-III	Discontinued	ITGAL/CD11A/LFA1A and ITGB2/CD18	1999	no	no	no
rozanolixizumab	Whole mAb	Approved	Active	FCGRT/FcRn	2016	YES	no	no
rozibafusp	Whole mAb Fusion	Phase-II	Active	ICOS/CD278	2018	YES	no	no
rulonilimab	Whole mAb	Phase-II/III	Discontinued	PDCD1/CD279/PD1	2021	no	no	no
runimotamab	Bispecific mAb	Phase-I	Active	ERBB2/CD340/HER2;CD3E	2020	YES;no	YES;no	YES;no
ruplizumab	Whole mAb	Phase-II	Discontinued	CD40LG/CD154	2000	YES	no	no
ruxoprubart	Whole mAb	Phase-II	Active	CFB/BFD	2024	no	no	no
ruzaltatug	Whole mAb ADC	TBC	TBC	ERBB3/HER3	2025	no	no	no
sabatolimab	Whole mAb	Phase-III	Discontinued	HAVCR2/TIM3	2019	no	no	no
sabestomig	Bispecific mAb	Phase-II	Active	PDCD1/CD279/PD1;HAVCR2/TIM3	2023	no;no	no;YES	no;no
sabirnetug	Whole mAb	Phase-II/III	Active	APP	2023	no	no	no
sacituzumab	Whole mAb ADC	Approved	Active	TACSTD2/TROP2/EGP1	2016	no	no	no
safimestomig	Bispecific Whole mAb	Phase-II	Active	IAP/CD47;PDL1/CD274	2024	YES;no	no;no	no;no
samalizumab	Whole mAb	Phase-I	Discontinued	MOX2/CD200	2010	no	no	no
samatatug	Whole mAb	Phase-I	Discontinued	F3/CD142	2024	no	no	no
samrotamab	Whole mAb ADC	Phase-I	Discontinued	LRRC15	2017	no	no	no
sarilumab	Whole mAb	Approved	Active	IL6R/CD126	2011	YES	no	no
sasanlimab	Whole mAb	Phase-III	Active	PDCD1/CD279/PD1	2019	YES	no	no
satralizumab	Whole mAb	Approved	NFD	IL6R/CD126	2015	no	no	no
satumomab	Whole mAb Radiolabelled	Approved	NFD	TAG72	1999	no	YES	no
secukinumab	Whole mAb	Approved	Active	IL17A	2009	YES	no	no
selicrelumab	Whole mAb	Phase-I	Discontinued	TNFRSF5/CD40	2016	no	no	no
semorinemab	Whole mAb	Phase-II	Discontinued	MAPT	2018	no	no	no
semzuvolimab	Whole mAb	Phase-III	Active	CD4	2022	no	no	no
seniprutug	Whole mAb	Phase-III	Active	TRBV9	2023	no	no	no
serclutamab	Whole mAb ADC	Phase-I	Discontinued	EGFR/ERBB1/HER1	2016	no	no	no
seribantumab	Whole mAb	Phase-II	Discontinued	ERBB3/HER3	2012	no	no	no
serplulimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2019	YES	no	no
setoxaximab	Whole mAb	Phase-II	Discontinued	Shiga Toxin Type 2	2012	no	no	no
setrusumab	Whole mAb	Phase-III	Active	SOST	2017	no	no	no
sibeprenlimab	Whole mAb	Phase-III	Active	TNFSF13/CD256/APRIL	2020	no	no	no
sifalimumab	Whole mAb	Phase-II	Discontinued	IFNA1	2009	YES	no	no
sigvotatug	Whole mAb	Phase-III	Active	ITGB6	2023	no	no	no
silevimig	Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3))	Preregistration	Active	Rabies Lyssavirus Glycoprotein G epitope III;Rabies Lyssavirus Glycoprotein G epitope I	2023	no;no	no;no	no;no
siltartoxatug	Whole mAb	Phase-III	Active	Clostridium tetani tetanus toxin (TeNT)	2024	no	no	no
siltuximab	Whole mAb	Approved	Active	IL6	2008	no	no	no
simaravibart	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2022	YES	no	no
simlukafusp	Whole mAb Fusion	Phase-I	Discontinued	FAP	2019	no	no	no
simridarlimab	Bispecific Mixed mAb/VH-VH-CH2-CH3	Phase-II	Active	IAP/CD47;PDL1/CD274	2021	no;no	no;no	no;no
simtuzumab	Whole mAb	Phase-II	Discontinued	LOXL2	2012	no	no	no
sintilimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2018	no	no	no
sipavibart	Whole mAb	Preregistration	Active	SARS-CoV-2 Spike RBD	2023	YES	no	YES
sirexatamab	Whole mAb	Phase-II	Active	DKK1	2021	no	no	no
sirtratumab	Whole mAb ADC	Phase-I	Active	SLITRK6	2017	no	no	no
sirukumab	Whole mAb	Preregistration (w)	Active	IL6	2011	no	no	no
socazolimab	Whole mAb	Approved	Active	PDL1/CD274	2021	no	no	no
sofituzumab	Whole mAb ADC	Phase-I	Discontinued	MUC16/CA125	2013	no	no	no
solabafusp	Antibody Fusion Protein	Phase-I/II	Active	PDL1/CD274	2024	no	no	no
solanezumab	Whole mAb	Phase-III	Active	APP	2008	no	YES	no
solitomab	Bispecific scFv	Phase-I	Discontinued	EPCAM/CD326;CD3E	2011	no;no	no;no	no;no
solnerstotug	Whole mAb	Phase-I/II	Active	VSIR/VISTA/B7H5/PD1H/SISP1	2024	no	YES	no
solrikitug	Whole mAb	Phase-I	Discontinued	TSLP	2023	no	no	no
sonavibart	Whole mAb	Phase-II	Discontinued	Influenza A HA	2024	YES	no	no
sonelokimab1	Trispecific Single Domains (VH-VH'-VH''); Bispecific Entry	Phase-III	Active	IL17A;ALB	2019	no;no	no;no	no;YES
sonelokimab2	Trispecific Single Domains (VH-VH'-VH''); Monospecific Entry	Phase-III	Active	IL17F	2019	no	no	no
sonesitatug	Whole mAb	Phase-III	Active	CLDN18	2024	no	no	no
sotevtamab	Whole mAb	Phase-II	Active	CLU	2021	no	no	no
sotiburafusp	Fusion Protein (whole mAb with protein)	Phase-II	Active	VEGFR-1	2023	no	no	no
sotigalimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2020	no	no	no
sotrovimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	no	YES	no
sovipostobart	Whole mAb	Phase-II	Active	CTLA4/CD152	2023	YES	no	no
spartalizumab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2017	no	no	no
spesolimab	Whole mAb	Approved	Active	IL36RN	2018	YES	no	no
spevatamig	Bispecific Whole mAb	Phase-I/II	Active	IAP/CD47;CLDN18	2024	no;no	no;no	no;no
stamulumab	Whole mAb	Phase-I/II	Discontinued	MSTN/GDF8/GDF-8/GDF8	2006	no	no	no
stapokibart	Whole mAb	Approved	Active	IL4R/CD124	2023	no	no	no
suciraslimab	Whole mAb	Preregistration	Active	SIGLEC2/CD22	2021	no	no	no
sudubrilimab	Whole mAb	Phase-II	Active	PDL1/CD274	2020	no	no	YES
sugemalimab	Whole mAb	Approved	Active	PDL1/CD274	2019	no	no	no
suptavumab	Whole mAb	Phase-III	Discontinued	Respiratory Syncytial Virus Glycoprotein F	2016	no	no	no
surovatamig	Bispecific Mixed Domains ((H-gamma4_L-kappa)_VH-G4(h-CH2-CH3))	Phase-III	Active	CD3D&CD3E;CD19	2024	no;no	no;no	no;no
surzebiclimab	Whole mAb	Phase-II	Active	HAVCR2/TIM3	2020	no	no	no
sutacimig	Bispecific Whole mAb	Phase-I/II	Active	F7a/F7A/FVIIa/FVIIA;TREML1/GLTL1825/PRO3438/TLT-1/TLT1	2024	YES;YES	no;no	no;no
sutimlimab	Whole mAb	Approved	NFD	C1S	2017	no	no	no
suvemcitug	Whole mAb	Phase-III	Active	VEGFA	2023	no	no	no
suvizumab	Whole mAb	Phase-I	Discontinued	HIV-1 gp120	2009	YES	no	no
suvonstobart	Whole mAb	TBC	TBC	CD24	2025	no	no	no
suvratoxumab	Whole mAb	Phase-III	Discontinued	Staphylococcus aureus Toxin A	2016	YES	no	no
tabalumab	Whole mAb	Phase-III	Discontinued	TNFSF13B/CD257/BAFF	2011	no	no	no
tabirafusp	Antibody Fusion Protein	Phase-III	Active	IL6	2024	no	no	no
tabituximab	Whole mAb ADC	Phase-I	Discontinued	FZD10/CD350	2018	no	no	no
tacatuzumab	Whole mAb ADC	Phase-I	Discontinued	Alpha Ferroprotein	2005	no	no	no
tadocizumab	Fab	Phase-II	Discontinued	ITGA2B and ITGB3	2005	no	no	no
tafasitamab	Whole mAb	Approved	Active	CD19	2018	no	no	no
tafolecimab	Whole mAb	Approved	Active	PCSK9	2019	no	no	no
tagitanlimab	Whole mAb	Approved	Active	PDL1/CD274	2021	no	no	no
talacotuzumab	Whole mAb	Phase-II	Active	IL3RA/CD123	2017	YES	no	no
talizumab	Whole mAb	Phase-II	Discontinued	IgE	2002	no	no	no
talquetamab	Bispecific mAb	Approved	Active	GPRC5D;CD3E	2019	YES;no	no;no	no;no
tamgiblimab	Whole mAb	Phase-II	Active	TIGIT/WUCAM/VSTM3	2021	no	no	no
tamrintamab	Whole mAb ADC	Phase-I	Discontinued	DPEP3	2018	YES	no	no
tamtuvetmab	Canine Whole mAb	Unknown	Active	CD52	2015	no	no	YES
tanezumab	Whole mAb	Phase-III	Discontinued	NGFB	2008	YES	no	no
tanruprubart	Whole mAb	TBC	TBC	C1q	2025	no	no	no
tarcocimab	Whole mAb	Phase-III	Active	VEGFA	2021	YES	no	YES
tarextumab	Whole mAb	Phase-II	Active	NOTCH2 and NOTCH3	2013	no	no	no
tarlatamab	Bispecific scFv	Approved	Active	DLL3;CD3E	2020	no;no	no;no	no;no
tarperprumig	Bispecific Single Domains (VH-VH')	Phase-II	Discontinued	ALB;CFP	2022	no;YES	no;no	no;no
tavolimab	Whole mAb	Phase-II	Discontinued	TNFSF4/CD134/CD252/OX40L	2016	no	no	no
tazlestobart	Whole mAb	TBC	Active	CTLA4/CD152	2024	YES	no	YES
tebentafusp	scFv Fusion	Approved	Active	CD3E	2017	no	no	no
tebotelimab	Bispecific scFv with Crossover	Phase-II/III	Discontinued	PDCD1/CD279/PD1;LAG3/CD223	2019	no;no	no;no	no;no
tecaginlimab	Bispecific mAb	Phase-I/II	Active	CD40;TNFRSF9/CD137/4-1BB	2021	no;no	no;no	no;no
teclistamab	Bispecific mAb	Approved	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2018	no;no	no;no	no;no
tecotabart	Whole mAb	Phase-I/II	Active	CLDN18	2024	no	no	no
tegoprubart	Whole mAb	Phase-II	Active	CD40LG/CD154	2023	YES	no	no
telazorlimab	Whole mAb	Phase-II	Active	TNFRSF4/CD134/OX40	2019	no	no	no
telikibart	Whole mAb	Phase-III	Active	IL4R/CD124	2024	no	no	no
telisotuzumab	Whole mAb ADC	Phase-I	Discontinued	MET/HGFR	2016	no	no	no
temelimab	Whole mAb	Phase-II	Active	MS-associated Retrovirus Envelope Protein	2018	no	no	no
temtokibart	Whole mAb	Phase-II	Active	IL22RA1	2023	no	no	no
tenatumomab	Whole mAb Radiolabelled	Phase-I	Discontinued	TNC	2007	no	no	no
teneliximab	Whole mAb	Phase-II	ND	TNFRSF5/CD40	2002	YES	no	no
teplizumab	Whole mAb	Approved	NFD	CD3E	2007	no	no	no
tepoditamab	Bispecific mAb	Phase-I	Discontinued	CLEC12A;CD3E	2017	no;no	no;no	no;no
teprotumumab	Whole mAb	Approved	Active	IGF1R/CD221	2009	no	no	no
teropavimab	Whole mAb	Phase-II	Active	HIV-1 gp120 CD4bs	2021	YES	YES	no
tesidolumab	Whole mAb	Phase-II	Active	C5	2014	no	no	no
tesnatilimab	Whole mAb	Phase-II	Active	KLRK1/NKG2D/CD314	2019	no	no	no
tezepelumab	Whole mAb	Approved	Active	TSLP	2015	YES	no	no
tibulizumab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	TNFSF13B/CD257/BAFF;IL17A	2017	no;no	no;no	no;YES
tidutamab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	SSTR2;CD3E	2018	no;no	no;no	no;no
tifcemalimab	Whole mAb	Phase-III	Active	BTLA/CD272	2019	no	no	no
tigatuzumab	Whole mAb	Phase-II	Discontinued	TNFRSF10B/CD262/DR5/TRAILR2	2007	no	no	no
tilatamig	Bispecific mAb	Phase-I	Active	MET/HGFR;EGFR/ERBB1/HER1	2024	no;no	no;no	no;no
tilavonemab	Whole mAb	Phase-II	Active	MAPT	2018	no	no	no
tildrakizumab	Whole mAb	Approved	Active	IL23A	2012	no	no	no
tilogotamab	Whole mAb	Phase-I/II	Active	TNFRSF10B/CD262/DR5/TRAILR2	2019	no	YES	no
tilrekimig1	Trispecific Mixed mAbs; Bispecific entry	Phase-II	Active	IL13;IL4	2025	no;no	no;no	no;no
tilrekimig2	Trispecific Mixed mAbs; Monospecific entry	Phase-II	Active	TSLP	2025	no	no	YES
tilvestamab	Whole mAb	Phase-I	Active	AXL/UFO	2019	no	no	no
timcevibart	Whole mAb	TBC	Active	SARS-CoV-2 Spike RBD	2023	YES	no	no
timigutuzumab	Whole mAb	Approved	NFD	ERBB2/CD340/HER2	1997	YES	YES	YES
timolumab	Whole mAb	Phase-II	Discontinued	AOC3/VAP1	2015	no	no	no
tinurilimab	Whole mAb	Phase-I	Discontinued	CEACAM6/CD66c	2019	no	no	no
tiragolumab	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2017	YES	no	no
tirnovetmab	Whole mAb (Canine)	Unknown	Active	IL31 (Canine)	2020	no	no	no
tislelizumab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2017	YES	no	no
tisotumab	Whole mAb	Approved	Active	F3/CD142	2015	no	no	no
tixagevimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	YES	YES
tixentamig	Bispecific Mixed Domains (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3)	TBC	TBC	CD3E;CLDN18	2025	no;no	no;no	no;no
tixestobart	Whole mAb	TBC	TBC	TNFRSF7/CD27	2025	no	no	no
tizetatug	Whole mAb	Phase-III	Active	TACSTD2/TROP2/EGP1	2024	no	no	no
tobemstomig	Bispecific mAb with Domain Crossover	Phase-II	Discontinued	PDCD1/CD279/PD1;LAG3/CD223	2022	no;no	no;no	no;no
tobevibart	Whole mAb	Phase-II	Active	Human Papillomavirus Envelope Protein	2022	no	no	no
tocilizumab	Whole mAb	Approved	Active	IL6R/CD126	2004	YES	no	no
tomaralimab	Whole mAb	Phase-II	Active	TLR2/CD282	2018	no	no	no
tomuzotuximab	Whole mAb	Phase-II	Active	EGFR/ERBB1/HER1	2016	no	YES	YES
toripalimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2018	YES	no	no
torudokimab	Whole mAb	Phase-II	Active	IL33	2020	no	no	no
torvutatug	Whole mAb ADC	Phase-I/II	Active	FOLR1	2025	no	no	no
tosatoxumab	Whole mAb	Phase-III	Active	Staphylococcus aureus Toxin A	2013	no	no	no
tovecimig	Bispecific Mixed mAb and scFv	Phase-II/III	Active	VEGFA	2024	YES;no	no;no	YES;no
tovetumab	Whole mAb	Phase-II	Discontinued	PDGFRA/CD140A	2013	no	no	no
tozorakimab	Whole mAb	Phase-III	Active	IL33	2020	no	no	no
trabikibart	Whole mAb	Phase-I	Active	CSF2RB/CD131/IL3RB/IL5RB	2023	YES	no	no
tralokinumab	Whole mAb	Approved	Active	IL13	2009	YES	no	no
trastuzumab	Whole mAb	Approved	NFD	ERBB2/CD340/HER2	1997	YES	YES	YES
traxivitug	Whole mAb	Phase-II	Active	BK Polyomavirus Major Capsid Protein VP1	2023	YES	no	no
tregalizumab	Whole mAb	Phase-II	Discontinued	CD4	2010	no	no	no
tremelimumab	Whole mAb	Approved	Active	CTLA4/CD152	2005	YES	no	no
trevogrumab	Whole mAb	Phase-II	Active	MSTN/GDF8/GDF-8	2015	no	no	no
trevotamig	Bispecific Mixed Domains (H-gamma1_L-kappa-scFvhl)	TBC	Active	EPCAM/CD326;CD3E	2024	no;no	no;no	no;no
trinbelimab	Whole mAb	TBC	Active	RhD/CD240D/RhPI	2021	no	no	no
trontinemab	Bispecific Mixed Format with Domain Crossover	Phase-II	Active	APP Abeta 1-40/42;TFRC/CD71	2022	YES;no	no;no	no;no
trosunilimab	Whole mAb	TBC	Active	ITGA4B7	2024	no	no	no
trovostobart	Whole mAb	TBC	TBC	VSIR/VISTA/B7H5/PD1H/SISP1	2025	no	no	no
tucotuzumab	Whole mAb ADC	Phase-II	Discontinued	EPCAM/CD326	2005	no	no	no
tulisokibart	Whole mAb	Phase-III	Active	TNFSF15/TL1A/VEGI	2022	no	no	no
tuparstobart	Whole mAb	Phase-II	Active	LAG3/CD223	2022	no	no	no
turenkibart	Whole mAb	Phase-II	Active	IL17A	2024	no	no	no
tusamitamab	Whole mAb	Phase-III	Discontinued	CEACAM5/CD66e	2020	YES	no	no
tuvonralimab	Whole mAb	Approved	Active	CTLA4/CD152	2021	no	no	no
ubamatamab	Bispecific mAb	Phase-II	Active	MUC16/CA125;CD3E	2021	no;no	no;no	no;no
ubletamig	Bispecific mAb	TBC	TBC	MUC16/CA125;CD28	2025	no;no	no;no	no;no
ublituximab	Whole mAb	Approved	Active	MS4A1/CD20	2010	no	no	no
ucenprubart	Whole mAb	Phase-II	Active	MOX2R/CD200R1	2023	no	no	no
ulenistamab	Whole mAb	Phase-II	Active	PAUF	2021	no	no	no
uliledlimab	Whole mAb	Phase-II	Active	NT5E/CALJA/CD73	2020	no	no	no
ulocuplumab	Whole mAb	Phase-I/II	Active	CXCR4/CD184	2013	no	no	no
ulviprubart	Whole mAb	Phase-II/III	Active	KLRG1	2022	no	no	no
umesolerbart	Whole mAb	Phase-III	Active	Bet v 1	2022	YES	no	no
umikibart	Whole mAb	Phase-II	Active	HGF	2024	no	no	no
umizortamig1	Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1)	TBC	Active	EGFRvIII;CD3E	2022	no;no	no;YES	no;YES
umizortamig2	Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2)	TBC	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2022	no;no	no;no	no;no
unasnemab	Whole mAb	Phase-II	Active	RGMA	2020	no	no	no
upanovimab	Whole mAb	Phase-II/III	Active	SARS-CoV-2 Spike RBD	2021	no	no	YES
upinitatug	Whole mAb	Phase-III	Discontinued	SLC34A2	2019	no	no	no
uprevstobart	Whole mAb	Phase-I	Discontinued	NT5E/CALJA/CD73	2023	no	no	no
urabrelimab	Whole mAb	Phase-I	Discontinued	IAP/CD47	2019	no	no	no
urelumab	Whole mAb	Phase-II	Active	TNFRSF9/CD137/4-1BB	2010	YES	no	no
urtoxazumab	scFv	Phase-II	Discontinued	Shiga-like Toxin II	2004	no	no	no
usilnetug	Whole mAb	TBC	Active	APP Abeta N3pGlu	2023	no	no	no
ustekinumab	Whole mAb	Approved	Active	IL12B/CLMFp40	2008	YES	no	no
utomilumab	Whole mAb	Phase-II	Active	TNFRSF9/CD137/4-1BB	2016	YES	no	no
vadastuximab	Whole mAb ADC	Phase-III	Discontinued	SIGLEC3/CD33/p67	2015	no	no	no
valanafusp	Whole mAb Fusion	Phase-II	Active	INSR/CD220	2017	no	YES	YES
vamikibart	Whole mAb	Phase-III	Active	IL6	2023	no	no	no
vandortuzumab	Whole mAb ADC	Phase-I	Discontinued	STEAP1	2014	no	no	no
vantictumab	Whole mAb	Phase-I	Discontinued	FZD	2013	no	no	no
vanucizumab	Bispecific mAb	Phase-II	Discontinued	ANGPT2;VEGFA	2014	YES;YES	no;no	no;YES
varisacumab	Whole mAb	Phase-II/III	Discontinued	VEGFA	2016	no	no	no
varlilumab	Whole mAb	Phase-II	Active	TNFRSF7/CD27	2014	no	no	no
varokibart	Whole mAb	Phase-II	Active	IL5	2022	no	no	no
vatelizumab	Whole mAb	Phase-II/III	Discontinued	ITGA2/CD49B	2011	no	no	no
vebanvibart	Whole mAb	Phase-II	Active	SARS-CoV-2 Spike RBD	2024	YES	no	YES
vecantoxatug	Whole mAb	Phase-III	Active	Clostridium tetani tetanus toxin (TeNT)	2025	no	no	no
vedolizumab	Whole mAb	Approved	Active	ITGA4B7	2008	no	no	no
velaprumig	Bispecific Mixed mAb and scFv	TBC	TBC	ALB;CD40LG/CD154	2025	no;YES	no;no	no;no
veligrotug	Whole mAb	Phase-III	Active	IGF1R/CD221	2023	no	no	no
velinotamig	Bispecific Whole mAb	Phase-II	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2024	no;no	no;no	no;no
veltuzumab	Whole mAb	Phase-II	Discontinued	MS4A1/CD20	2007	no	no	no
venanprubart	Whole mAb	Phase-II	Active	BTLA/CD272	2023	YES	no	no
vensobafusp	Fusion Protein (whole mAb with protein)	Phase-II	Active	C5	2023	no	no	no
vepsitamab	Bispecific (scFv-scFv-scFc)	Phase-I	Discontinued	MUC17;CD3E	2021	no;no	no;no	no;no
verekitug	Whole mAb	Phase-II	Active	CRLF2	2023	no	no	no
verenafusp	Fab Fusion Protein	Phase-II/III	Active	INSR/CD220	2024	no	YES	YES
verzistobart	Whole mAb	Phase-II	Active	HAVCR2/TIM3	2023	no	no	no
vesencumab	Whole mAb	Phase-I	Discontinued	NRP1	2010	YES	no	no
vibecotamab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	IL3RA/CD123;CD3E	2018	no;no	no;no	no;no
vibostolimab	Whole mAb	Phase-III	Discontinued	TIGIT/WUCAM/VSTM3	2019	no	no	no
vilamakitug	Whole mAb	Phase-III	Active	IL1A	2022	no	no	no
vilastobart	Whole mAb	Phase-I/II	Active	CTLA4/CD152	2023	YES	no	YES
vilobelimab	Whole mAb	Approved	Active	C5	2019	no	no	no
vipalanebart	Whole mAb	Phase-II	Active	ADCYAP1/PACAP	2023	no	no	no
visilizumab	Whole mAb	Phase-III	Discontinued	CD3E	2000	no	no	no
vislarafusp	Fusion Protein	Phase-I/II	Active	SIRPA	2024	no	YES	YES
visugromab	Whole mAb	Phase-II	Active	GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB	2022	no	no	no
vixarelimab	Whole mAb	Phase-II	Active	OSMR	2020	no	no	no
vixticibart	Whole mAb	TBC	Active	NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA	2024	YES	no	no
vixtimotamab	Bispecific Homodimer (VK-VH-VL'-VH'; Tandem diabody)	Phase-I	Discontinued	CD3E;SIGLEC3/CD33/p67	2020	no;no	no;no	no;no
vobarilizumab	Bispecific Single Domains (VH-VH')	Phase-II	Discontinued	IL6R/CD126;ALB	2015	YES;no	no;no	no;no
vobramitamab	Whole mAb	Phase-II/III	Active	B7H3/CD276	2022	no	no	no
vofatamab	Whole mAb	Phase-I/II	Active	FGFR3/CD333	2018	no	no	YES
volagidemab	Whole mAb	Phase-II	Active	GCCR/NR3C1	2018	no	YES	no
volociximab	Whole mAb	Phase-II	Discontinued	ITGA5B1	2005	no	no	no
volrustomig	Bispecific mAb	Phase-III	Active	CTLA4/CD152;PDCD1/CD279/PD1	2022	YES;no	no;no	no;no
vonlerolizumab	Whole mAb	Phase-II	Discontinued	TNFRSF4/CD134/OX40	2015	YES	no	no
vonsetamig	Bispecific mAb	Phase-I/II	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2023	no;no	no;no	no;no
vopikitug	Whole mAb	Phase-I	Active	IL2RA/CD25	2023	YES	no	no
vopratelimab	Whole mAb	Phase-II	Active	ICOS/CD278	2017	no	no	no
vorsetuzumab	Whole mAb ADC	Phase-II	Discontinued	TNFSF7/CD70/CD27LG	2012	no	no	no
voxalatamab	Bispecific mAb	Phase-I	Discontinued	FOLH1/GCPII/PSMA;CD3E	2021	no;no	no;no	no;no
vudalimab	Bispecific Mixed mAb and scFv	Phase-II	Active	CTLA4/CD152;PDCD1/CD279/PD1	2020	no;no	no;no	YES;no
vulinacimab	Whole mAb	Phase-I	Discontinued	KDR/CD309/VEGFR2	2019	no	no	no
vunakizumab	Whole mAb	Approved	Active	IL17A	2016	no	no	no
xaluritamig	Bispecific Mixed mAb and scFv	Phase-III	Active	STEAP1;CD3	2022	YES;no	no;no	no;no
xeligekimab	Whole mAb	Approved	Active	IL17A	2021	no	no	no
xentuzumab	Whole mAb	Phase-II	Active	IGF1 and IGF2	2015	no	no	no
xirestomig	Bispecific (G1-scFv_L2 dimer)	Phase-I	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2023	no;no	no;no	no;no
zadoprubart	Whole mAb	TBC	Active	BTLA/CD272	2024	no	no	no
zagotenemab	Whole mAb	Phase-II	Discontinued	MAPT	2019	no	no	no
zalifrelimab	Whole mAb	Phase-II	Active	CTLA4/CD152	2018	no	no	no
zaltenibart	Whole mAb	Phase-II	Active	MASP3	2024	no	no	no
zalutumumab	Whole mAb	Phase-II	Discontinued	EGFR/ERBB1/HER1	2005	no	no	no
zamerovimab	Whole mAb	Phase-III	Active	Rabies Virus Spike Glycoprotein G	2021	no	no	no
zampilimab	Whole mAb	Phase-I/II	Active	TGM2	2018	no	no	no
zamubafusp	Antibody Fusion Protein	TBC	Active	Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope)	2024	no	no	no
zanidatamab	Bispecific mAb	Approved	Active	ERBB2/CD340/HER2;ERBB2/CD340/HER2	2019	no;YES	no;YES	YES;YES
zanolimumab	Whole mAb	Phase-III	Discontinued	CD4	2004	no	no	no
zansecimab	Whole mAb	Phase-II	Discontinued	ANGPT2	2020	no	no	no
zeleciment	Fab	TBC	Active	TFRC/CD71	2023	no	no	no
zelminemab	Whole mAb	Phase-II	Active	ADCYAP1R1/PAC1	2019	no	no	no
zeluvalimab	Whole mAb	Phase-I/II	Active	PDCD1/CD279/PD1	2020	no	no	no
zemocimig	Bispecific mAb	TBC	TBC	F9a;F10	2025	YES;YES	no;no	no;no
zenocutuzumab	Bispecific mAb	Approved	Active	ERBB3/HER3;ERBB2/CD340/HER2	2017	YES;YES	no;no	no;no
zeripatamig	Bispecific mAb	Phase-I	Discontinued	IAP/CD47;CD19	2022	YES;no	no;no	no;no
zifibancimig	Bispecific mAb	Phase-I	Active	ANPT2;VEGFA	2022	no;no	no;no	no;no
zigakibart	Whole mAb	Phase-III	Active	TNFSF13/CD256/APRIL	2022	no	no	no
zilovertamab	Whole mAb	Phase-II	Active	ROR1	2020	no	no	no
ziltivekimab	Whole mAb	Phase-III	Active	IL6	2019	no	no	no
zimberelimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
zinlirvimab	Whole mAb	Phase-II	Active	HIV-1 gp120 V3	2022	YES	YES	YES
zolbetuximab	Whole mAb	Approved	Active	CLDN18	2017	no	no	no
zovostotug	Whole mAb	Phase-I/II	Active	CD163	2023	no	no	no
zuberitamab	Whole mAb	Phase-II	Discontinued	MS4A1/CD20	2019	no	no	YES
zubotamig	Bispecific mAb ((H-gamma1_L-kappa)_(H-gamma1_Llambda2))	Phase-I/II	Active	VTCN1/B7H4;CD3E	2024	no;no	no;no	no;no